US20170137525A1 - Methods of treating skin disorders using an anti-il-31ra antibody - Google Patents
Methods of treating skin disorders using an anti-il-31ra antibody Download PDFInfo
- Publication number
- US20170137525A1 US20170137525A1 US15/411,640 US201715411640A US2017137525A1 US 20170137525 A1 US20170137525 A1 US 20170137525A1 US 201715411640 A US201715411640 A US 201715411640A US 2017137525 A1 US2017137525 A1 US 2017137525A1
- Authority
- US
- United States
- Prior art keywords
- cells
- skin
- antibody
- seq
- cla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 208000017520 skin disease Diseases 0.000 title claims description 15
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 claims abstract description 195
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 claims abstract description 188
- 201000004700 rosacea Diseases 0.000 claims abstract description 16
- 201000009053 Neurodermatitis Diseases 0.000 claims abstract description 13
- 206010034277 Pemphigoid Diseases 0.000 claims abstract description 13
- 208000000594 bullous pemphigoid Diseases 0.000 claims abstract description 13
- 208000017940 prurigo nodularis Diseases 0.000 claims abstract description 13
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims abstract description 9
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 9
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims abstract description 9
- 201000005962 mycosis fungoides Diseases 0.000 claims abstract description 9
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims abstract description 9
- 206010039710 Scleroderma Diseases 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims description 57
- 125000000539 amino acid group Chemical group 0.000 claims description 51
- 230000027455 binding Effects 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 230000003472 neutralizing effect Effects 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 abstract description 36
- 239000005557 antagonist Substances 0.000 abstract description 32
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 19
- 208000010247 contact dermatitis Diseases 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 17
- 231100000360 alopecia Toxicity 0.000 abstract description 16
- 206010012442 Dermatitis contact Diseases 0.000 abstract description 14
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 abstract description 11
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 abstract description 11
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 abstract description 11
- 230000003111 delayed effect Effects 0.000 abstract description 11
- 241000700584 Simplexvirus Species 0.000 abstract description 9
- 102100021596 Interleukin-31 Human genes 0.000 description 176
- 101710181613 Interleukin-31 Proteins 0.000 description 172
- 210000001744 T-lymphocyte Anatomy 0.000 description 122
- 102000005962 receptors Human genes 0.000 description 116
- 108020003175 receptors Proteins 0.000 description 116
- 108090000765 processed proteins & peptides Proteins 0.000 description 113
- 210000004027 cell Anatomy 0.000 description 109
- 102000004196 processed proteins & peptides Human genes 0.000 description 108
- 229920001184 polypeptide Polymers 0.000 description 102
- 206010012438 Dermatitis atopic Diseases 0.000 description 94
- 201000008937 atopic dermatitis Diseases 0.000 description 94
- 241000699670 Mus sp. Species 0.000 description 75
- 210000003491 skin Anatomy 0.000 description 67
- 108090000623 proteins and genes Proteins 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 34
- 102000040430 polynucleotide Human genes 0.000 description 33
- 108091033319 polynucleotide Proteins 0.000 description 33
- 239000002157 polynucleotide Substances 0.000 description 33
- 201000010099 disease Diseases 0.000 description 32
- 208000003251 Pruritus Diseases 0.000 description 30
- 238000006748 scratching Methods 0.000 description 26
- 230000002393 scratching effect Effects 0.000 description 26
- 230000004054 inflammatory process Effects 0.000 description 25
- 206010061218 Inflammation Diseases 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 21
- 238000001514 detection method Methods 0.000 description 21
- 102000004127 Cytokines Human genes 0.000 description 20
- 230000003676 hair loss Effects 0.000 description 20
- 208000024963 hair loss Diseases 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 201000004681 Psoriasis Diseases 0.000 description 17
- 239000000556 agonist Substances 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 239000003446 ligand Substances 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000003364 immunohistochemistry Methods 0.000 description 15
- 230000003902 lesion Effects 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 201000004624 Dermatitis Diseases 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 206010000496 acne Diseases 0.000 description 14
- 210000001616 monocyte Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 208000002874 Acne Vulgaris Diseases 0.000 description 13
- 230000003248 secreting effect Effects 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 12
- 206010070834 Sensitisation Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 229940092253 ovalbumin Drugs 0.000 description 12
- 230000008313 sensitization Effects 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 102000054727 Serum Amyloid A Human genes 0.000 description 11
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000007390 skin biopsy Methods 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 230000005951 type IV hypersensitivity Effects 0.000 description 11
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 206010040882 skin lesion Diseases 0.000 description 10
- 231100000444 skin lesion Toxicity 0.000 description 10
- 230000007815 allergy Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 229960002504 capsaicin Drugs 0.000 description 9
- 235000017663 capsaicin Nutrition 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 7
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 210000005069 ears Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000001732 sebaceous gland Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010003645 Atopy Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 6
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 6
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 108700028909 Serum Amyloid A Proteins 0.000 description 6
- 101150108167 TAC1 gene Proteins 0.000 description 6
- 241000030538 Thecla Species 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000002391 anti-complement effect Effects 0.000 description 6
- 108010008730 anticomplement Proteins 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 210000003071 memory t lymphocyte Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000037311 normal skin Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 101710190759 Serum amyloid A protein Proteins 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000007310 pathophysiology Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000001185 psoriatic effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000000106 sweat gland Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 4
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- -1 Lif Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000003171 anti-complementary effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 125000000837 carbohydrate group Chemical group 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000002650 immunosuppressive therapy Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001823 pruritic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241001635598 Enicostema Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000002090 Fibronectin type III Human genes 0.000 description 2
- 108050009401 Fibronectin type III Proteins 0.000 description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 2
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 2
- 108010054395 P-selectin ligand protein Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- 206010037083 Prurigo Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004658 acute-phase response Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000045345 human IL31 Human genes 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 230000013727 interleukin-31 production Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000017452 Epidermal disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010019972 Herpes viral infections Diseases 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000005705 Keratin-5 Human genes 0.000 description 1
- 108010070553 Keratin-5 Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 208000010557 Lipid storage disease Diseases 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 101001043822 Mus musculus Interleukin-31 Proteins 0.000 description 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 101800000399 Neurokinin A Proteins 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 208000010346 Sphingolipidoses Diseases 0.000 description 1
- 201000001307 Sphingolipidosis Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- 101710113649 Thyroid peroxidase Proteins 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000804 eccrine gland Anatomy 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036736 holocrine secretion Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000045410 human IL31RA Human genes 0.000 description 1
- 102000043719 human OSMR Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000014416 lysosomal lipid storage disease Diseases 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000647 material safety data sheet Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940062713 mite extract Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the skin plays an important role in the immune system and consists of layers.
- the epidermis is a surface layer. Underneath the epidermis is the dermis, a layer of connective tissue. Underneath the dermis, is the hypodermis, a layer of large amounts of adipose tissue. Circulating T lymphocytes migrate to the skin under normal and inflammatory conditions.
- the cutaneous lymphocyte antigen (CLA) is considered a homing receptor for T cells with tropism for the skin. Santamaria-Babi, L., Eur. J. Dermatol. 14:13-18, 2004.
- CLA is a carbohydrate structure which is expressed on memory T cells as an epitope of the single cell-surface protein named P-selectin glycoprotein ligand-1 (PSGL-1) and facilitates binding of T cells to E-selectin, an inducible adhesion molecule expressed on vascular endothelium.
- PSGL-1 P-selectin glycoprotein ligand-1
- CLA+ T cells Several diseases of the skin are known to express high levels of CLA+ T cells, including atopic dermatitis, contact dermatitis, drug-induced allergic reactions, skin-tropic viruses and viral associated pruritis, vitiligo, cutaneous T cell lymphoma, alopecia aerata, acne rosacea, acne vulgaris, prurigo nodularis, and bullous pemphigoid. There is a need to treat such skin T cell mediated diseases.
- the demonstrated in vivo activities of the cytokine family illustrate the enormous clinical potential of, and need for, other cytokines, cytokine agonists, and cytokine antagonists.
- the present invention addresses these needs by providing a method of treating such diseases with IL-31RA antagonists, e.g., IL-31RA soluble receptor or neutralizing IL-31RA monoclonal antibody or fragment, a receptor for the newly identified IL-31 cytokine.
- IL-31 when over-expressed in mice, results in dermatitis-like symptoms. Both skin-homing T cells and epidermal keratinocytes have been implicated in the pathology of skin diseases in humans.
- a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one.
- affinity tag is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate.
- Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl.
- allelic variant is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence.
- allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.
- amino-terminal and “carboxyl-terminal” are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.
- complement/anti-complement pair denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions.
- biotin and avidin are prototypical members of a complement/anti-complement pair.
- Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like.
- the complement/anti-complement pair preferably has a binding affinity of ⁇ 10 9 M ⁇ 1 .
- polynucleotide molecule denotes a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5′ ATGCACGGG 3′ is complementary to 5′ CCCGTGCAT 3′.
- contig denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to “overlap” a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5′-ATGGCTTAGCTT-3′ (SEQ ID NO:18) are 5′-TAGCTTgagtct-3′ (SEQ ID NO:19) and 3′-gtcgacTACCGA-5′ (SEQ ID NO:20).
- degenerate nucleotide sequence denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide).
- Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).
- expression vector is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription.
- additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc.
- Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
- isolated when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems.
- isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones.
- Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5′ and 3′ untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).
- an “isolated” polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue.
- the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure.
- the term “isolated” does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.
- operably linked when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.
- ortholog denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.
- Parenters are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, ⁇ -globin, ⁇ -globin, and myoglobin are paralogs of each other.
- polynucleotide is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5′ to the 3′ end.
- Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated “bp”), nucleotides (“nt”), or kilobases (“kb”). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded.
- double-stranded molecules When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term “base pairs”. It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired.
- polypeptide is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides”.
- promoter is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5′ non-coding regions of genes.
- a “protein” is a macromolecule comprising one or more polypeptide chains
- a protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
- receptor denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell.
- a bioactive molecule i.e., a ligand
- Membrane-bound receptors are characterized by a multi-peptide structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell.
- Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids.
- receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).
- secretory signal sequence denotes a DNA sequence that encodes a polypeptide (a “secretory peptide”) that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized.
- secretory peptide a polypeptide that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized.
- the larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.
- a “soluble receptor” is a receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides that lack transmembrane and cytoplasmic domains. Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate, or immunoglobulin constant region sequences. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis. Soluble receptor polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively.
- splice variant is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.
- the present invention provides novel methods of using IL-31RA antagonists in detection, diagnosis, and treatment of diseases, in particular, diseases that have a high correlation of cutaneous lymphocyte antigen (CLA).
- CLA cutaneous lymphocyte antigen
- the present invention is based in part upon the discovery that a previously identified cytokine, IL-31 is expressed by skin-homing T cells, but not gut-homing T cells.
- IL-31 is a recently discovered protein having the structure of a four-helical-bundle cytokine. This cytokine was previously identified as IL-31 and is fully described in U.S. patent application Ser. No. 10/352,554, filed Jan. 21, 2003. See published U.S. Patent Application No. 2003-0224487, and PCT application WO 03/060090, all herein incorporated by reference. See also, Dillon, et al., Nature Immunol. 5:752-760, 2004. IL-31 is a ligand with high specificity for the receptor IL-31RA and at least one additional subunit comprising OncostatinM receptor beta (OSMRbeta).
- OSMRbeta OncostatinM receptor beta
- the native polynucleotide and polypeptide sequences for human IL-31 are shown in SEQ ID NOs:1 and 2, respectively.
- the native polynucleotide and polypeptide sequences for mouse IL-31 are shown in SEQ ID NOs:3 and 4, respectively.
- IL-31 also means and is interchangeably referred to as Zcytor17lig
- IL-31RA also means and is interchangeably referred to as Zcytor17, as used in U.S. patent publication number 20030224487 (herein incorporated by reference), as shown above.
- the heterodimeric receptor for IL-31 was also described in 20030224487 as comprising zcytor17 (HUGO name, IL-31RA) and with at least one additional subunit comprising OncostatinM receptor beta (OSMRbeta).
- the native polynucleotide and polypeptide sequences for the “long” form of IL-31RA are shown in SEQ ID NOs:5 and 6, respectively.
- the native polynucleotide and polypeptide sequences for the “short” form of IL-31RA are shown in SEQ ID NOs:7 and 8, respectively.
- truncated forms of IL-31RA polypeptide appear to be naturally expressed. Both forms encode soluble IL-31RA receptors.
- the “long” soluble IL-31RA polynucleotide and polypeptide sequences are shown in SEQ ID NOs:9 and 10, respectively.
- the “short” soluble IL-31RA polynucleotide and polypeptide sequences are shown in SEQ ID NOs:11 and 12, respectively.
- the native polynucleotide and polypeptide sequences for mouse IL-31RA are shown in SEQ ID NOs:13 and 14, respectively.
- the native polynucleotide and polypeptide sequences for human OSMRbeta are shown in SEQ ID NOs:15 and 16, respectively. See PCT applications WO 02/00721 and WO 04/003140, both of which are incorporated by reference.
- the secretory signal sequence of IL-31 is comprised of amino acid residues 1 (Met) to 23 (Ala), and the mature polypeptide is comprised of amino acid residues 24 (Ser) to 164 (Thr) as shown in SEQ ID NO:2.
- Further N-terminal sequencing analysis of purified IL-31 from 293T cells showed an N-terminus at residue 27 (Leu) as shown in SEQ ID NO:2, with the mature polypeptide comprised of amino acid residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2.
- Cytokine receptor subunits are characterized by a multi-domain structure comprising an extracellular domain, a transmembrane domain that anchors the polypeptide in the cell membrane, and an intracellular domain.
- the extracellular domain may be a ligand-binding domain
- the intracellular domain may be an effector domain involved in signal transduction, although ligand-binding and effector functions may reside on separate subunits of a multimeric receptor.
- the domains and structural features of the IL-31RA polypeptides are further described below.
- SEQ ID NO:6 Analysis of the IL-31RA polypeptide encoded by the DNA sequence of SEQ ID NO:5 revealed an open reading frame encoding 732 amino acids (SEQ ID NO:6) comprising a predicted secretory signal peptide of 19 amino acid residues (residue 1 (Met) to residue 19 (Ala) of SEQ ID NO:6), and a mature polypeptide of 713 amino acids (residue 20 (Ala) to residue 732 (Val) of SEQ ID NO:6).
- the receptor comprises an extracellular domain (residues 20 (Ala) to 519 (Glu) of SEQ ID NO:6; residues 33 (Ala) to 532 (Glu) of SEQ ID NO:8) which includes a cytokine-binding domain of approximately 200 amino acid residues (residues 20 (Ala) to 227 (Pro) of SEQ ID NO:6; residues 33 (Ala) to 240 (Pro) of SEQ ID NO:8); a domain linker (residues 122 (Thr) to 125 (Pro) of SEQ ID NO:6; residues 135 (Thr) to 138 (Pro) of SEQ ID NO:8); a penultimate strand region (residues 194 (Phe) to 202 (Arg) of SEQ ID NO:
- conserved receptor features in the encoded receptor include (as shown in SEQ ID NO:6) a conserved Cys residue at position 30 (position 43 as shown in SEQ ID NO:8), CXW motif (wherein X is any amino acid) at positions 40-42 of SEQ ID NO:6 (positions 53-55 as shown in SEQ ID NO:8), Trp residue at position 170 of SEQ ID NO:6 (position 183 as shown in SEQ ID NO:8), and a conserved Arg residue at position 202 of SEQ ID NO:6 (position 215 as shown in SEQ ID NO:8).
- the corresponding polynucleotides encoding the IL-31RA polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NOs:5 and 7.
- truncated forms of the IL-31RA polypeptide appear to be naturally expressed. Both forms encode soluble zcytor17 receptors.
- a polynucleotide encoding a “long-form” of the soluble zcytor17 receptor, truncated within the fibronectin type III domain, is shown in SEQ ID NO:9 and the corresponding polypeptide is shown in SEQ ID NO:10.
- This truncated form encodes residues 1 (Met) through 324 (Lys) of SEQ ID NO:6, and thus comprises an intact signal sequence, WSXWS (SEQ ID NO:17) motif, linker, cytokine binding domain, penultimate strand, and conserved, Cys, CXW motif, Trp and Arg residues as described above.
- a polynucleotide encoding a “short-form” of the soluble IL-31RA receptor, truncated at the end of the cytokine binding domain is shown in SEQ ID NO:11 and the corresponding polypeptide is shown in SEQ ID NO:12.
- This truncated form encodes a 239 residue polypeptide that is identical to residues 1 (Met) through 225 (Glu) of SEQ ID NO:6 and then diverges, and thus comprises an intact signal sequence, WSXWS (SEQ ID NO:17) motif, linker, cytokine binding domain, penultimate strand, and conserved, Cys, CXW motif, Trp and Arg residues as described above.
- IL-31 mRNA and protein expression is restricted to the skin-homing CLA+ T cell population in both atopic dermatitis (AD) patients and normal individuals, while analysis of the receptor for IL-31, IL-31RA, by immunohistochemistry (IHC) suggests slightly higher levels of IL-31RA expression on skin keratinocytes in skin biopsies from acute and chronic AD sufferers compared to normal individuals.
- IHC immunohistochemistry
- IL-31 results in pruritus and the development of skin dermatitis resembling human atopic dermatitis (AD)
- Immunohistochemistry (IHC) studies shown herein show that IL-31RA protein was expressed by skin keratinocytes and infiltrating macrophages in skin biopsies from AD patients. Comparisons between AD patients and normal individuals suggested that IL-31RA was expressed at higher levels on epidermal keratinocytes in the AD samples. Skin cell infiltrates, which were present at greater numbers in skin of AD patients compared to normal individuals, expressed IL-31 mRNA.
- IL-31 mRNA and protein expression are largely restricted to CD45RO+ CLA+ skin-homing T cells in AD and normal volunteers.
- circulating CLA+ T cells from AD patients are capable of producing higher levels of IL-31 compared to CLA+ T cells from normal individuals, though there is large variability between patient samples.
- IL-31 is produced both locally in the skin and by skin infiltrating cells.
- Local production of cytokines in tissues by T cells is thought to be a key mechanism for disease pathogenesis in AD and increased numbers of T cells both in circulation and in skin is thought to correlate with disease.
- CLA+ T cells from AD patients are reported to exist in a more activated state compared to cells from normal individuals. See Akdis M, J Immunol., 159:4611-4619, 1997. Consequently, the threshold of stimulation required for the production of IL-31 by CLA+ T cells may differ between dermatitis patients and control subjects. As shown herein, circulating CLA+ T cells from AD patients after 24 hours of stimulation with sub-optimal concentrations of anti-CD3 in the absence of anti-CD28 have the capacity to produce higher levels of IL-31 compared to cells from normal individuals.
- Example 1 demonstrates that circulating CLA+ T cells from some AD patients produce higher levels of IL-31 compared to cells from normal individuals.
- the detection of IL-31 in patients of such a subpopulation using the bioassay provided herein, or with any assay that detects IL-31 produced by circulating T cells in the blood, may be useful to determine if an IL-31 antagonist will be useful as treatment for diseases wherein the presence of IL-31 causes inflammation.
- a cell line that is dependent on the OSMRbeta and IL-31RA linked pathway for survival and growth in the absence of other growth factors can be used to measure the activity of IL-31.
- growth factor-dependent cell lines include BaF3, FDC-P1, and MO7e.
- BaF3 cell line see Palacios and Steinmetz, ( Cell, 41:727-734, 1985) and Mathey-Prevot et al., ( Mol. Cell. Biol., 6:4133-4135, 1986).
- FDC-P1 cell line see Hapel et al. ( Blood, 64:786-790, 1984).
- For information on the MO7e cell line see Kiss et al., ( Leukemia, 7:235-240, 1993).
- the amino acid sequence for the OSMRbeta, and IL-31RA receptors indicated that the encoded receptors belonged to the Class I cytokine receptor subfamily that includes, but is not limited to, the receptors for IL-2, IL-4, IL-7, Lif, IL-12, IL-15, EPO, TPO, GM-CSF and G-CSF (for a review see, Cosman, “The Hematopoietin Receptor Superfamily” in Cytokine 5(2): 95-106, 1993).
- the IL-31RA receptor is fully described in PCT Patent Application No. US01/20484 (WIPO publication No. WO 02/00721).
- tissue distribution of the mRNA of the IL-31RA receptor revealed expression in activated CD4+ and CD8+ T-cell subsets, CD14+ monocytes, and weaker expression in CD19+ B-cells. Moreover, the mRNA was present in both resting or activated monocytic cell lines THP-1 (ATCC No. TIB-202), U937 (ATCC No. CRL-1593.2) and HL60 (ATCC No. CCL-240).
- Antigenic epitope-bearing peptides and polypeptides preferably contain at least four to ten amino acids, at least ten to fourteen amino acids, or about fourteen to about thirty amino acids of the extracellular domains of SEQ ID NO:6 or SEQ ID NO:8.
- Such epitope-bearing peptides and polypeptides can be produced by fragmenting the extracellular domain of IL-31RA polypeptide, or by chemical peptide synthesis, as described herein.
- epitopes can be selected by phage display of random peptide libraries (see, for example, Lane and Stephen, Curr. Opin. Immunol. 5:268 (1993); and Cortese et al., Curr. Opin. Biotechnol.
- the IL-31RA polypeptides of the present invention can be produced, purified and refolded by methods well-known in the art and as described in PCT applications WO 02/00721 and WO 04/003140. It is preferred to purify the polypeptides of the present invention to 80% purity, more preferably to 90% purity, even more preferably 95% purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents.
- a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.
- the present invention provides methods for using IL-31RA antagonists, including anti-IL-31RA antibodies and fragments, soluble IL-31RA receptors, and soluble IL-31RA/OSMRbeta receptors for reducing, inhibiting, or preventing inflammation in cell microenvironments where one or more cells in the microenvironment is/are T cells that are positive for the cutaneous lymphocyte antigen.
- IL-31RA antagonists including anti-IL-31RA antibodies and fragments, soluble IL-31RA receptors, and soluble IL-31RA/OSMRbeta receptors for reducing, inhibiting, or preventing inflammation in cell microenvironments where one or more cells in the microenvironment is/are T cells that are positive for the cutaneous lymphocyte antigen.
- Antibodies from an immune response generated by inoculation of an animal with IL-31RA antigens can be isolated and purified are known in the art and are described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in Immunology , Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition , Cold Spring Harbor, N.Y., 1989; and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications , CRC Press, Inc., Boca Raton, Fla., 1982.
- polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a IL-31RA polypeptide or a fragment thereof.
- the immunogenicity of an IL-31RA polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant.
- Polypeptides useful for immunization also include fusion polypeptides, such as fusions of IL-31RA or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein.
- the polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is “hapten-like”, such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.
- a macromolecular carrier such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid
- antibodies includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as Fab fragment, Fab′ fragment, F(ab′) 2 fragment, single chain Fv (scFv) proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included.
- Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally “cloaking” them with a human-like surface by replacement of exposed residues, wherein the result is a “veneered” antibody).
- humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics.
- biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced.
- human antibodies can be produced in transgenic, non-human animals that have been engineered to contain human immunoglobulin genes as disclosed in WIPO Publication No. WO 98/24893. It is preferred that the endogenous immunoglobulin genes in these animals be inactivated or eliminated, such as by homologous recombination.
- Antibodies are considered to be specifically binding if: 1) they exhibit a threshold level of binding activity, and 2) they do not significantly cross-react with related polypeptide molecules.
- a threshold level of binding is determined if anti-IL-31RA antibodies herein bind to an IL-31RA polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non-IL-31RA) polypeptide. It is preferred that the antibodies exhibit a binding affinity (Ka) of 10 6 M ⁇ 1 or greater, preferably 10 7 M ⁇ 1 or greater, more preferably 108 M ⁇ 1 or greater, and most preferably 10 9 M ⁇ 1 or greater.
- the binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672, 1949).
- the present invention provides a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of an anti-IL-31RA antibody or fragment to the patient, wherein the anti-IL-31RA antibody or fragment binds with amino acid residues 20-519 of SEQ ID NO:6 or portion thereof, or amino acid residues 33-532 of SEQ ID NO:8 or portion thereof, and wherein the anti-IL-31RA antibody or fragment prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus.
- the anti-IL-31RA antibody may optionally be a polyclonal antibody or a neutralizing monoclonal antibody (the present invention also provides for a hybridoma for producing the neutralizing IL-31RA monoclonal antibody).
- the anti-IL-31RA antibody fragment may optionally be a Fab fragment, a Fab′ fragment, a F(ab′) 2 fragment, single chain Fv (scFV), dual specific antibody, domain antibody, or bispecific antibody.
- the anti-IL-31RA antibody or fragment may bind with amino acid residues 20-277 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8.
- the anti-IL-31RA antibody or fragment may bind with about 4-10 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.
- the anti-IL-31RA antibody or fragment may bind with about 10-14 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.
- the anti-IL-31RA antibody or fragment may bind with about 14-30 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.
- the anti-IL-31 antibody or fragment may be further conjugated to a polyethylene glycol or to human serum albumin.
- the present invention also provides for a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of a soluble IL-31RA receptor to the patient, wherein the soluble IL-31RA receptor binds with an IL-31 polypeptide consisting of amino acid residues 1-164 SEQ ID NO:2, and wherein the soluble IL-31RA receptor prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus.
- the soluble IL-31RA receptor may comprise amino acid residues 20-519 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8, amino acid residues 1-324 of SEQ ID NO:10, or amino acid residues 1-239 of SEQ ID NO:12.
- the soluble IL-31RA receptor may be further conjugated to the Fc region of the various immunoglobulins (IgG, IgA, IgD, IgM or IgE).
- the soluble IL-31RA receptor may be an IL-31RA homodimer or an IL-31RA/OSMRbeta heterodimer.
- the soluble IL-31RA receptor may bind with an IL-31 polypeptide comprising, consisting essentially of, consisting of amino acid residues 24-164 of SEQ ID NO:2 or 27-164 of SEQ ID NO:2.
- the soluble IL-31RA receptor may be further conjugated to a polyethylene glycol or to human serum albumin.
- the present invention also provides isolated IL-31RA encoding nucleic acid molecules that can hybridize under stringent conditions to nucleic acid molecules having the nucleotide sequence of nucleotides 58-1557 of SEQ ID NO:5 or nucleotides 97-1596 SEQ ID NO:7, or to nucleic acid molecules having a nucleotide sequence complementary to nucleotides 58-1557 of SEQ ID NO:5 or to nucleotides 97-1596 SEQ ID NO:7.
- stringent conditions are selected to be about 5*C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.
- the Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
- a pair of nucleic acid molecules can hybridize if the nucleotide sequences have some degree of complementarity.
- Hybrids can tolerate mismatched base pairs in the double helix, but the stability of the hybrid is influenced by the degree of mismatch.
- the Tm of the mismatched hybrid decreases by 1° C. for every 1-1.5% base pair mismatch. Varying the stringency of the hybridization conditions allows control over the degree of mismatch that will be present in the hybrid. The degree of stringency increases as the hybridization temperature increases and the ionic strength of the hybridization buffer decreases.
- the Tm for a specific target sequence is the temperature (under defined conditions) at which 50% of the target sequence will hybridize to a perfectly matched probe sequence.
- Those conditions which influence the Tm include, the size and base pair content of the polynucleotide probe, the ionic strength of the hybridization solution, and the presence of destabilizing agents in the hybridization solution.
- Sequence analysis software such as OLIGO 6.0 (LSR; Long Lake, Minn.) and Primer Premier 4.0 (Premier Biosoft International; Palo Alto, Calif.), as well as sites on the Internet, are available tools for analyzing a given sequence and calculating Tm based on user defined criteria. Such programs can also analyze a given sequence under defined conditions and identify suitable probe sequences. Typically, hybridization of longer polynucleotide sequences, >50 base pairs, is performed at temperatures of about 20-25° C. below the calculated Tm. For smaller probes, ⁇ 50 base pairs, hybridization is typically carried out at the Tm or 5-10° C. below the calculated Tm. This allows for the maximum rate of hybridization for DNA-DNA and DNA-RNA hybrids.
- the nucleic acid molecules can be washed to remove non-hybridized nucleic acid molecules under stringent conditions, or under highly stringent conditions.
- Typical stringent washing conditions include washing in a solution of 0.5 ⁇ -2 ⁇ SSC with 0.1% sodium dodecyl sulfate (SDS) at 55-65° C.
- nucleic acid molecules encoding a variant IL-31RA polypeptide hybridize with a nucleic acid molecule having the nucleotide sequence of nucleotides 58-1557 of SEQ ID NO:5 (or its complement) or nucleotides 97-1596 SEQ ID NO:7 (or its complement) under stringent washing conditions, in which the wash stringency is equivalent to 0.5 ⁇ -2 ⁇ SSC with 0.1% SDS at 55-65° C., including 0.5 ⁇ SSC with 0.1% SDS at 55° C., or 2 ⁇ SSC with 0.1% SDS at 65° C.
- One of skill in the art can readily devise equivalent conditions, for example, by substituting SSPE for SSC in the wash solution.
- Typical highly stringent washing conditions include washing in a solution of 0.1 ⁇ -0.2 ⁇ SSC with 0.1% sodium dodecyl sulfate (SDS) at 50-65° C.
- SDS sodium dodecyl sulfate
- nucleic acid molecules encoding a variant IL-31RA polypeptide hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1 ⁇ -0.2 ⁇ SSC with 0.1% SDS at 50-65° C., including 0.1 ⁇ SSC with 0.1% SDS at 50° C., or 0.2 ⁇ SSC with 0.1% SDS at 65° C.
- the present invention also provides isolated IL-31RA polypeptides that have a substantially similar sequence identity to the polypeptides having amino acid residues 20-519 of SEQ ID NO:6 and/or amino acid residues 33-532 of SEQ ID NO:8, or their orthologs.
- substantially similar sequence identity is used herein to denote polypeptides comprising at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99-0.5%, or greater than 99.5% sequence identity to the sequences shown in amino acid residues 20-519 of SEQ ID NO:6 and/or amino acid residues 33-532 of SEQ ID NO:8, or their orthologs.
- the present invention further includes nucleic acid molecules that encode such polypeptides. Methods for determining percent identity are described PCT publications WO 02/00721 (incorporated by reference) and 04/003140 (incorporated by reference).
- the present invention provides a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of an anti-IL-31RA antibody or fragment to the patient, wherein the anti-IL-31RA antibody or fragment binds with an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or great than 99.5% sequence identity with amino acid residues 20-519 of SEQ ID NO:6 or portion thereof, or amino acid residues 33-532 of SEQ ID NO:8 or portion thereof, and wherein the anti-IL-31RA antibody or fragment prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal
- the anti-IL-31RA antibody may optionally be a polyclonal antibody or a neutralizing monoclonal antibody (the present invention also provides for a hybridoma for producing the neutralizing IL-31RA monoclonal antibody).
- the anti-IL-31RA antibody fragment may optionally be a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, single chain Fv (scFV), dual specific antibody, domain antibody, or bispecific antibody.
- the anti-IL-31RA antibody or fragment may bind with amino acid residues 20-277 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8.
- the anti-IL-31RA antibody or fragment may bind with about 4-10 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.
- the anti-IL-31RA antibody or fragment may bind with about 10-14 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.
- the anti-IL-31RA antibody or fragment may bind with about 14-30 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8.
- the anti-IL-31 antibody or fragment may be further conjugated to a polyethylene glycol or to human serum albumin.
- the present invention also provides for a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of a soluble IL-31RA receptor to the patient, wherein the soluble IL-31RA receptor has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or great than 99.5% sequence identity with amino acid residues 20-519 of SEQ ID NO:6 or portion thereof, or amino acid residues 33-532 of SEQ ID NO:8, and wherein the soluble IL-31RA receptor binds with an IL-31 polypeptide consisting of amino acid residues 1-164 SEQ ID NO:2, and wherein the soluble IL-31RA receptor prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic
- the soluble IL-31RA receptor may comprise amino acid residues 20-519 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8, amino acid residues 1-324 of SEQ ID NO:10, or amino acid residues 1-239 of SEQ ID NO:12.
- the soluble IL-31RA receptor may be further conjugated to the Fc region of the various immunoglobulins (IgG, IgA, IgD, IgM or IgE).
- the soluble IL-31RA receptor may be an IL-31RA homodimer or an IL-31RA/OSMRbeta heterodimer.
- the soluble IL-31RA receptor may bind with an IL-31 polypeptide comprising, consisting essentially of, consisting of amino acid residues 24-164 of SEQ ID NO:2 or 27-164 of SEQ ID NO:2.
- the soluble IL-31RA receptor may be further conjugated to a polyethylene glycol or to human serum albumin.
- assays known to those skilled in the art can be utilized to detect antibodies which bind to IL-31RA proteins or polypeptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual , Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant IL-31RA protein or polypeptide.
- Antibodies to IL-31RA may be used for tagging cells that express IL-31RA; for isolating IL-31RA by affinity purification; for diagnostic assays for determining circulating levels of IL-31RA polypeptides; for detecting or quantitating soluble IL-31RA as a marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block IL-31 activity in vitro and in vivo.
- Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates.
- Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications.
- antibodies to IL-31RA or fragments thereof may be used in vitro to detect denatured IL-31RA or fragments thereof in assays, for example, Western Blots or other assays known in the art.
- Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like.
- Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria, toxin, saporin, Pseudomonas exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance).
- Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin.
- cytotoxic drugs such as adriamycin.
- the detectable or cytotoxic molecule can be conjugated with a member of a complementary/anticomplementary pair, where the other member is bound to the polypeptide or antibody portion.
- biotin/streptavidin is an exemplary complementary/anticomplementary pair.
- Polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues).
- a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest.
- the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule.
- Such domain-complementary molecule fusion proteins thus represent a generic targeting carrier or vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/cytotoxic molecule conjugates.
- IL-31 mRNA and protein expression is restricted to the skin-homing CLA+ T cell population in humans.
- an antagonist to IL-31RA including an antibody or fragment thereof or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors) antagonist will be useful in treating, ablating, inhibiting the progression of, and/or reducing the severity of skin and epidermal diseases which have expression of CLA+ T cells.
- Such diseases include, for example, atopic dermatitis, contact dermatitis, psoriasis, drug-induced allergic reactions, skin-tropic viruses and viral associated pruritis, vitiligo, cutaneous T cell lymphoma, alopecia aerata, acne rosacea, acne vulgaris, prurigo nodularis, and bullous pemphigoid.
- AD Atopic dermatitis
- atopic dermatitis is a chronically relapsing inflammatory skin disease with a dramatically increasing incidence over the last decades.
- Clinically AD is characterized by highly pruritic often excoriated plaques and papules that show a chronic relapsing course.
- the diagnosis of AD is mostly based on major and minor clinical findings. See Hanifin J M, Arch Dermatol: 135, 1551 (1999). Histopathology reveals spongiosis, hyper and focal parakeratosis in acute lesions, whereas marked epidermal hyperplasia with hyper and parakeratosis, acanthosis/hypergranulosis and perivascular infiltration of the dermis with lymphocytes and abundant mast cells are the hallmarks of chronic lesions.
- T cells play a central role in the initiation of local immune responses in tissues and evidence suggests that skin-infiltrating T cells in particular, may play a key role in the initiation and maintenance of disregulated immune responses in the skin.
- CLA+ cutaneous lymphocyte-associated Ag
- E-selectin an inducible adhesion molecule on endothelium
- epicutaneous sensitization of mice using OVA can also be used as a model to induce antigen-dependent epidermal and dermal thickening with a mononuclear infiltrate in skin of sensitized mice. This usually coincides with elevated serum levels of total and specific IgE, however no skin barrier dysfunction or pruritus normally occurs in this model. Seespergel J. M., et al., J Clin Invest, 101: 1614, (1998). This protocol can be modified in order to induce skin barrier disregulation and pruritis by sensitizing DO11.10 OVA TCR transgenic mice with OVA. Increasing the number of antigen-specific T cells that could recognize the sensitizing antigen may increase the level of inflammation in the skin to induce visible scratching behaviour and lichenification/scaling of the skin.
- An IL-31RA neutralizing antagonist could be effective in inhibiting, reducing, minimizing or preventing atopic dermatitis reactions. See Example 3 for an in vivo model for testing the effect of an IL-31 antagonist in an atopic dermatitis model.
- Allergic contact dermatitis is defined as a T cell mediated immune reaction to an antigen that comes into contact with the skin.
- the CLA+ T cell population is considered to be involved in the initiation of dermatitis since allergen dependent T cell responses are largely confined to the CLA+ population of cells (See Santamaria-Babi, L. F., et al., J Exp Med: 181, 1935, (1995)).
- Recent data has found that only memory (CD45RO+) CD4+ CLA+ and not CD8+ T cells proliferate and produce both type-1 (IFN- ⁇ ) and type-2 (IL-5) cytokines in response to nickel, a common contact hypersensitivity allergen.
- cells expressing CLA in combination with CD4, CD45RO (memory) or CD69 are increased after nickel-specific stimulation and express the chemokine receptors CXCR3, CCR4, CCR10 but not CCR6. See Moed H., et al., Br J Dermatol: 51, 32, (2004).
- An IL-31RA neutralizing antagonist e.g., antibody or fragment thereof or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors), could be effective in inhibiting, reducing, minimizing or preventing contact dermatitis reactions. See Example 2 for an in vivo model for testing the effect of an IL-31 antagonist in a contact dermatitis model.
- Drug-induced delayed type cutaneous allergic reactions are very heterogeneous and may mirror many distinct pathophysiological events. See Brockow K., et al., Allergy, 57, 45 (2002). Immunological mechanisms involved in these reactions have been shown as either antibody or cell mediated. In immediate drug allergy an IgE-mediated antibody reaction can be demonstrated by a positive skin prick and/or intradermal test after 20 min, whereas non-immediate reactions to drugs can occur more than one hour after last drug intake and are often T-cell mediated.
- Non-immediate T-cell mediated delayed type reactions can occur in patients with adverse drug reactions to penicillins for example Proliferative T cell responses to penicillins have been shown to be restricted to the memory (CD45RO+) CLA+ subpopulation of T cells from penicillin allergic patients whereas the CD45RO+ CLA ⁇ subset shows no proliferative response. See Blanca M., Leyva L., et al., Blood Cells Mol Dis: 31, 75 (2003). Delayed-type hypersensitivity (DTH) reactions can be artificially reproduced in mice, allowing assessment of factors that may be involved in the initiation and perpetuation of the DTH response.
- DTH Delayed-type hypersensitivity
- An IL-31RA neutralizing antagonist e.g., antibody or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors), could be effective in inhibiting, reducing, minimizing or preventing delayed type hypersensitivity reactions. See Example 4 for an in vivo model of testing the effect of an IL-31 antagonist in a DTH model.
- Toxic epidermal necrolysis is a very rare but extremely severe drug reaction characterized by widespread apoptosis of epidermis with extensive blisters. Studies have shown that lymphocytes infiltrating the blister are CLA+ T cells and can exhibit cytotoxicity towards epidermal keratinocytes. See Leyva L., et al., J Allergy Clin Immunol: 105, 157 (2000); and Nassif A., Bensussan A., et al., J Allergy Clin Immunol: 114, 1209 2004).
- a transgenic mouse system whereby OVA is expressed under the control of the keratin-5 (K5) promoter in the epidermal and hair follicular keratinocytes of mice, has been generated to establish an animal model for TEN.
- OVA specific CD8+ T cells when adoptively transferred into K5-OVA mice, undergo activation and proliferation in the skin-draining lymph nodes and target the skin of K5-OVA mice, resulting in development of skin lesions that are reminiscent of TEN. See Azukizawa H., et al., Eur J Immunol: 33, 1879 (2003).
- An IL-31RA neutralizing antagonist e.g., antibody or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors), could be effective in inhibiting, reducing, minimizing or preventing TEN reactions.
- Bullous pemphigoid is a subepidermal disorder which manifests as subepidermal blisters with a dermal infiltrate of neutrophils and eosinophils. Diagnosis is characterized by the presence of antigen-specific antibodies against specific adhesion proteins of the epidermis and dermal-epidermal junction. See Jordon R. E., et al., JAMA: 200, 751 (1967). Studies analyzing the role of T cells in the pathogenesis of bullous pemphigoid by analysis of PBL and skin blister T cells have found a predominance of CLA+ T cells expressing increased levels of Th2-cytokines like IL-4 and IL-13.
- Alopecia areata is regarded as a tissue-restricted autoimmune disease of hair follicles in which follicular activity is arrested because of the continued activity of lymphocytic infiltrates. AA results in patches of complete hair loss anywhere on the body, though actual loss of hair follicles does not occur, even in hairless lesions. Although clinical signs of inflammation are absent, skin biopsies from sites of active disease show perifollicular lymphocytic inflammation of primarily CD4+ cells, along with a CD8+ intrafollicular infiltrate. See Kalish R. S. & Gilhar A. J Investig Dermatol Symp Proc: 8, 164 (2003).
- Acne vulgaris a disorder of the pilosebaceous apparatus, is the most common skin problem of adolescence. Abnormalities in follicular keratinization are thought to produce the acne lesion. Acne rosacea is differentiated from acne vulagaris by the presence of red papules, pustules, cysts and extensive telangiectasias, but the absence of comedones (white heads). Increased sebum excretion from sebaceous glands is a major factor in the pathophysiology of acne vulgaris.
- sebaceous gland functions are also associated with the development of acne, including sebaceous proinflammatory lipids; different cytokines produced locally; periglandular peptides and neuropeptides, such as corticotrophin-releasing hormone, which is produced by sebocytes; and substance P, which is expressed in the nerve endings at the vicinity of healthy-looking glands of acne patients. See Zouboulis C. C. Clin Dermatol: 22, 360 (2004).
- CD4+ T cells produce IL-31 and IHC analysis of skin for IL-31 expression suggests that IL-31 is expressed in sebaceous and sweat glands.
- IL-31 stimulation of epidermal keratinocytes induces expression of chemokines which likely results in cellular infiltration suggesting that IL-31 may contribute to the pro-inflammatory response in skin.
- IL-31 may therefore contribute to the pathophysiology of acne rosacea and acne vulgaris.
- an IL-31RA antagonist such as an anti-IL-31RA antibody or fragment thereof, or an IL-31RA soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors) can be useful to treat, reduce the severity of, inhibit the progression of, ablate, and/or eliminate one or more symptoms associated with acne rosacea and acne vulgaris.
- Prurigo nodularis is an eruption of lichenified or excoriated nodules caused by intractable pruritus that is difficult to treat. While chronic rubbing results in lichenification, and scratching in linear excoriations, individuals who pick and gouge at their itchy, irritated skin tend to produce markedly thickened papules known as prurigo nodules. Although prurigo nodularis is not specific to atopic dermatitis, many patients with these nodules also have an atopic reaction, which manifests as allergic rhinitis, asthma, or food allergy. T cells represent the majority of infiltrating cells in prurigo lesions and these lesions often represents the most pruritic skin lesion in atopy patients.
- Topical treatment of prurigo nodularis with capsaicin an anti-pruritic alkaloid that interferes with the perception of pruritis and pain by depletion of neuropeptides like substance P in small sensory cutaneous nerves, has proven to be an effective and safe regimen resulting in clearing of the skin lesions. See Stander S., et al., J Am Acad Dermatol: 44, 471 (2001). Studies of the itch response in NC/Nga mice using capsaicin treatment showed that the spontaneous development of dermatitis lesions was almost completely prevented. Furthermore, the elevation of serum IgE levels was significantly suppressed and infiltrating eosinophils and mast cell numbers in lesional skin of capsaicin treated mice were reduced.
- IL-31 Chronic delivery of IL-31 induces pruritis and alopecia in mice followed by the development of skin lesions resembling dermatitis suggesting that IL-31 induces itching. See Dillon S. R., et al., Nat Immunol: 5, 752 (2004).
- the involvement of IL-31 was tested in induction of the itch response by two methods (i) capsaicin treatment of IL-31-treated mice and (ii) IL-31 treatment of Tac1 knockout mice, which have significantly reduced nociceptive pain responses because of lack of expression of neuropeptides in Example 5.
- neutralization of IL-31 in IL-31 treated mice could prevent pruritis and alopecia was tested in Example 5.
- Herpes Simplex Virus (HSV)-specific CD8+ T cells in the peripheral blood and HSV-specific CD8+ T cells recovered from herpes lesions express high levels of CLA where as non-skin-tropic herpes virus-specific CD8+ T cells lack CLA expression.
- HSV-2 reactive CD4+ T lymphocytes also express CLA, but at levels lower than those previously observed for CD8+ T lymphocytes. See Gonzalez J. C., et al., J Infect Dis: 191, 243 (2005). Pruritis has also been associated with herpes viral infections (See Hung K.
- IL-31 producing T cells may be involved in the pathophysiology of viral infections.
- Inflammation is a protective response by an organism to fend off an invading agent. Inflammation is a cascading event that involves many cellular and humoral mediators. On one hand, suppression of inflammatory responses can leave a host immunocompromised; however, if left unchecked, inflammation can lead to serious complications including chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and the like), septic shock and multiple organ failure. Importantly, these diverse disease states share common inflammatory mediators. The collective diseases that are characterized by inflammation have a large impact on human morbidity and mortality.
- anti-inflammatory molecules such as anti-IL-31RA antibodies and fragments thereof, and IL-31RA soluble receptors as described herein, could have crucial therapeutic potential for a vast number of human and animal diseases, from asthma and allergy to autoimmunity and septic shock.
- use of anti-inflammatory anti-IL-31RA antibodies and fragments thereof, and IL-31RA soluble receptors as described herein can be used therapeutically as IL-31RA antagonists for treating, reducing the severity of, inhibiting the progression of, and ablating diseases such as arthritis, endotoxemia, inflammatory bowel disease, psoriasis, related disease and the like.
- IL-31 has been shown to induce several chemokine and cytokine genes in normal human epidermal keratinocytes (NHEKs), including genes encoding GRO ⁇ , (CXCL1), TARC (CCl17), MIP3 ⁇ , (CCL19), MDC (CCL22), MIP-3 (CCL23), MIP-1 ⁇ (CCL4), and I-309.
- NHEKs normal human epidermal keratinocytes
- TARC and MDC bind CCR4, a chemokine receptor associated with Th2-type T cells and predominantly expressed by CLA+ T cells in peripheral blood.
- chemokines have been implicated in the recruitment of T cells into the skin of AD patients suggesting that these chemokines contribute to the inflammatory process associated with the pathogenesis of AD. See Example 10 for a model to measure the reduction in TARC and MDC levels by administering an IL-31 antagonist.
- Psoriasis is a chronic skin condition that affects more than seven million Americans. Psoriasis occurs when new skin cells grow abnormally, resulting in inflamed, swollen, and scaly patches of skin where the old skin has not shed quickly enough. Plaque psoriasis, the most common form, is characterized by inflamed patches of skin (“lesions”) topped with silvery white scales. Psoriasis may be limited to a few plaques or involve moderate to extensive areas of skin, appearing most commonly on the scalp, knees, elbows and trunk. Although it is highly visible, psoriasis is not a contagious disease. The pathogenesis of the diseases involves chronic inflammation of the affected tissues.
- Anti-IL-31RA antibodies and fragment thereof and soluble receptors could serve as a valuable therapeutic to treat, inhibit the progression of, reduce the severity of, reduce inflammation and pathological effects in psoriasis, other inflammatory skin diseases, skin and mucosal allergies, and related diseases.
- Psoriasis is a T-cell mediated inflammatory disorder of the skin that can cause considerable discomfort. It is a disease for which there is no cure and affects people of all ages. Psoriasis affects approximately two percent of the populations of European and North America. Although individuals with mild psoriasis can often control their disease with topical agents, more than one million patients worldwide require ultraviolet or systemic immunosuppressive therapy. Unfortunately, the inconvenience and risks of ultraviolet radiation and the toxicities of many therapies limit their long-term use. Moreover, patients usually have recurrence of psoriasis, and in some cases rebound, shortly after stopping immunosuppressive therapy.
- the present invention provides a method for inhibiting activation or differentiation of monocytes/macrophages.
- Monocytes are incompletely differentiated cells that migrate to various tissues where they mature and become macrophages.
- Macrophages play a central role in the immune response by presenting antigen to lymphocytes and play a supportive role as accessory cells to lymphocytes by secreting numerous cytokines. Macrophages can internalize extracellular molecules and upon activation have an increased ability to kill intracellular microorganisms and tumor cells. Activated macrophages are also involved in stimulating acute or local inflammation.
- the molecules of the present invention have particular use in the monocyte/macrophage arm of the immune system.
- Methods are known that can assess such activity.
- interferon gamma IFN- ⁇
- IFN- ⁇ interferon gamma
- THP-1 cells ATCC No. TIB-202
- interferon gamma could suggest that this receptor is involved in monocyte activation.
- Monocytes are incompletely differentiated cells that migrate to various tissues where they mature and become macrophages. Macrophages play a central role in the immune response by presenting antigen to lymphocytes and play a supportive role as accessory cells to lymphocytes by secreting numerous cytokines.
- Macrophages can internalize extracellular molecules and upon activation have an increased ability to kill intracellular microorganisms and tumor cells. Activated macrophages are also involved in stimulating acute or local inflammation. Moreover, monocyte-macrophage function has been shown to be abnormal in a variety of diseased states. For example see, Johnston, R B, New Eng. J. Med. 318:747-752, 1998.
- agonists of IL-31RA receptor such as agonist IL-31RA antibody
- agonist IL-31RA antibody agonist IL-31RA antibody
- depressed migration of monocytes has been reported in populations with a predisposition to infection, such as newborn infants, patients receiving corticosteroid or other immunosuppressive therapy, and patients with diabetes mellitus, burns, or AIDS.
- Agonists for IL-31RA, such as agonist IL-31RA antibody could result in an increase in the ability of monocytes to migrate and possibly prevent infection in these populations.
- IL-31RA receptor such as agonist IL-31RA antibody
- monocyte cytotoxicity has been reported in patients with cancer and Wiskott-Aldrich syndrome (eczema, thrombocytopenia, and recurrent infections).
- the monocyte-macrophage system is prominently involved in several lipid-storage diseases (sphingolipidoses) such as Gaucher's disease. Resistance to infection can be impaired because of a defect in macrophage function, which could be treated by agonists to IL-31RA receptor such as agonist IL-31RA antibody.
- sphingolipidoses lipid-storage diseases
- Resistance to infection can be impaired because of a defect in macrophage function, which could be treated by agonists to IL-31RA receptor such as agonist IL-31RA antibody.
- IL-31RA agonists and antagonists in diseases that have a high correlation of CLA+ T cells.
- IL-31 is expressed in a T-cell, macrophage and monocyte-specific manner, and these diseases involve abnormalities in monocytic cells, such as cell proliferation, function, localization, and activation
- the polynucleotides, polypeptides, and antibodies of the present invention can be used to as diagnostics to detect such monocytic cell abnormalities, and indicate the presence of disease.
- Such methods involve taking a biological sample from a patient, such as blood, saliva, or biopsy, and comparing it to a normal control sample.
- Histological, cytological, flow cytometric, biochemical and other methods can be used to determine the relative levels or localization of IL-31, or cells expressing IL-31, i.e., monocytes, in the patient sample compared to the normal control.
- a change in the level (increase or decrease) of IL-31 expression, or a change in number or localization of monocytes (e.g., increase or infiltration of monocytic cells in tissues where they are not normally present) compared to a control would be indicative of disease.
- Such diagnostic methods can also include measuring TARC and MDC, for example. Such methods are well known in the art and disclosed herein.
- IL-31RA antagonists such as anti-IL-31RA antibodies
- IL-31RA antagonists such as soluble IL-31RA and IL-31RA/OSMRbeta receptors
- the present invention includes the use of IL-31RA antibodies and fragments thereof as well as IL-31RA soluble receptors (IL-31RAa do IL-31RA/OSMRbeta) which can be administered to a subject which has excess IL-31.
- IL-31RA antagonists e.g., anti-IL-31RA antibodies and fragments thereof and soluble IL-31RA and soluble IL-31RA/OSMRbeta receptors
- Suitable subjects include mammals, such as humans
- IL-31 has been shown to be expressed in activated mononuclear cells, and may be involved in regulating inflammation. As such, antibodies and soluble receptors of the present invention can be assayed and used for their ability to modify inflammation, or can be used as a marker for inflammation. Methods to determine proinflammatory and anti-inflammatory qualities of IL-31 are known in the art and discussed herein. Moreover, it may be involved in up-regulating the production of acute phase reactants, such as serum amyloid A (SAA), ⁇ 1-antichymotrypsin, and haptoglobin, and that expression of IL-31RA receptor may be increased upon injection of lipopolysaccharide (LPS) in vivo that are involved in inflammatory response (Dumoutier, L.
- SAA serum amyloid A
- ⁇ 1-antichymotrypsin ⁇ 1-antichymotrypsin
- haptoglobin haptoglobin
- the acute phase protein SAA is implicated in the pathogenesis of several chronic inflammatory diseases, is implicated in atherosclerosis and rheumatoid arthritis, and is the precursor to the amyloid A protein deposited in amyloidosis (Uhlar, C M and Whitehead, supra.).
- a ligand such as IL-31 that acts as a pro-inflammatory molecule and induces production of SAA
- antagonists would be useful in treating inflammatory disease and other diseases associated with acute phase response proteins induced by the ligand. Such antagonists are provided by the present invention.
- a method of reducing inflammation comprises administering to a mammal with inflammation a therapeutically effective amount of a composition comprising anti-IL-31RA antibody (e.g., neutralizing antibody) or fragment thereof, or a soluble receptor (e.g., IL-31RA and IL-31RA/OSMRbeta soluble receptors) that is sufficient to reduce inflammation.
- a composition comprising anti-IL-31RA antibody (e.g., neutralizing antibody) or fragment thereof, or a soluble receptor (e.g., IL-31RA and IL-31RA/OSMRbeta soluble receptors) that is sufficient to reduce inflammation.
- a method of suppressing an inflammatory response in a mammal with inflammation can comprise: (1) determining a level of serum amyloid A protein; (2) administering a composition comprising an anti-IL-31RA antibody as described herein or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors) in an acceptable pharmaceutical carrier; (3) determining a post administration level of serum amyloid A protein; (4) comparing the level of serum amyloid A protein in step (1) to the level of serum amyloid A protein in step (3), wherein a lack of increase or a decrease in serum amyloid A protein level is indicative of suppressing an inflammatory response.
- anti-IL-31RA antibodies and fragments thereof that block the binding and/or signaling of IL-31 to IL-31RA, and soluble IL-31RA receptors (IL-31RA and IL-31RA/OSMRbeta) that bind IL-31 and thus prevent the binding of IL-31 to cellular-based IL-31RA are useful to antagonize or block signaling of IL-31 and are thus useful in the treatment of, inhibit the progression of, reduce the severity of, reduce one or more symptoms associated with Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus.
- Anti-IL-31RA antibodies, and soluble IL-31RA (IL-31RA and IL-31RA/OSMRbeta soluble receptors) comprising receptors are useful as antagonists of IL-31. Such antagonistic effects can be achieved by direct neutralization or binding of its natural ligand.
- the soluble receptors can bind IL-31 and act as carrier or carrier proteins, in order to transport IL-31 to different tissues, organs, and cells within the body.
- the soluble receptors can be fused or coupled to molecules, polypeptides or chemical moieties that direct the soluble-receptor-Ligand complex to a specific site, such as a tissue, specific immune cell, monocytes, or tumor.
- soluble receptors described herein or antibodies (and fragments thereof) of the present invention can be used to specifically direct the action of a pro-inflammatory IL-31 ligand. See, Cosman, D. Cytokine 5: 95-106, 1993; and Fernandez-Botran, R. Exp. Opin. Invest. Drugs 9:497-513, 2000.
- IL-31 may also be used within diagnostic systems for the detection of circulating levels of ligand, and in the detection of acute phase inflammatory response.
- antibodies or other agents that specifically bind to IL-31 e.g., soluble IL-31RA and soluble IL-31RA/OSMRbeta, can be used to detect circulating IL-31 polypeptides. Elevated or depressed levels of ligand or receptor polypeptides may be indicative of pathological conditions, including inflammation or cancer.
- detection of acute phase proteins or molecules such as IL-31 can be indicative of a chronic inflammatory condition in certain disease states (e.g., rheumatoid arthritis). Detection of such conditions serves to aid in disease diagnosis as well as help a physician in choosing proper therapy.
- the dosage of administered IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. Typically, it is desirable to provide the recipient with a dosage of IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor which is in the range of from about 1 pg/kg to 10 mg/kg (amount of agent/body weight of patient), although a lower or higher dosage also may be administered as circumstances dictate.
- a dosage of IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor which is in the range of from about 1 pg/kg to 10 mg/kg (amount of agent/body weight of patient), although a lower or higher dosage also may be administered as circumstances dictate.
- One skilled in the art can readily determine such
- Administration of IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor to a subject can be topical, intradermal, inhalant, intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, by perfusion through a regional catheter, or by direct intralesional injection.
- the administration may be by continuous infusion or by single or multiple boluses.
- Additional routes of administration include oral, mucosal-membrane, pulmonary, and transcutaneous.
- Oral delivery is suitable for polyester microspheres, zein microspheres, proteinoid microspheres, polycyanoacrylate microspheres, and lipid-based systems (see, for example, DiBase and Morrel, “Oral Delivery of Microencapsulated Proteins,” in Protein Delivery: Physical Systems , Sanders and Hendren (eds.), pages 255-288 (Plenum Press 1997)).
- the feasibility of an intranasal delivery is exemplified by such a mode of insulin administration (see, for example, Hinchcliffe and Illum, Adv. Drug Deliv. Rev. 35:199 (1999)).
- Dry or liquid particles comprising IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor can be prepared and inhaled with the aid of dry-powder dispersers, liquid aerosol generators, or nebulizers (e.g., Pettit and Gombotz, TIBTECH 16:343 (1998); Patton et al., Adv. Drug Deliv. Rev. 35:235 (1999)).
- This approach is illustrated by the AERX diabetes management system, which is a hand-held electronic inhaler that delivers aerosolized insulin into the lungs.
- Transdermal delivery using electroporation provides another means to administer IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor (Potts et al., Pharm. Biotechnol. 10:213 (1997)).
- a pharmaceutical composition comprising a IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier.
- a composition is said to be a “pharmaceutically acceptable carrier” if its administration can be tolerated by a recipient patient.
- Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier.
- Other suitable carriers are well-known to those in the art. See, for example, Gennaro (ed.), Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company 1995).
- an IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor and a pharmaceutically acceptable carrier are administered to a patient in a therapeutically effective amount.
- a combination of an IL-31RA antibody (antagonist and agonist) or a soluble IL-31RA receptor (e.g., IL-31RA homodimer and a zcytor17/OSMRbeta heterodimer) and a pharmaceutically acceptable carrier is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant.
- An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.
- an agent used to treat inflammation is physiologically significant if its presence alleviates at least a portion of the inflammatory response.
- a pharmaceutical composition comprising an IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor can be furnished in liquid form, in an aerosol, or in solid form.
- Liquid forms are illustrated by injectable solutions, aerosols, droplets, topological solutions and oral suspensions.
- Exemplary solid forms include capsules, tablets, and controlled-release forms. The latter form is illustrated by miniosmotic pumps and implants (Bremer et al., Pharm. Biotechnol.
- An IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor can be encapsulated within liposomes using standard techniques of protein microencapsulation (see, for example, Anderson et al., Infect. Immun. 31:1099 (1981), Anderson et al., Cancer Res. 50:1853 (1990), and Cohen et al., Biochim. Biophys. Acta 1063:95 (1991), Alving et al. “Preparation and Use of Liposomes in Immunological Studies,” in Liposome Technology, 2nd Edition, Vol.
- liposomes may contain a variety of components.
- liposomes may comprise lipid derivatives of poly(ethylene glycol) (Allen et al., Biochim. Biophys. Acta 1150:9 (1993)).
- dosage forms can be devised by those skilled in the art, as shown, for example, by Ansel and Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems, 5 th Edition (Lea & Febiger 1990), Gennaro (ed.), Remington's Pharmaceutical Sciences, 19 th Edition (Mack Publishing Company 1995), and by Ranade and Hollinger, Drug Delivery Systems (CRC Press 1996).
- T cell subsets human PBMCs from the donors were isolated using standard Ficoll gradient centrifugation. Total T cells were then isolated using the T Cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer's instructions. Separation efficiency was assessed using standard flow cytometry and determined to be >95% T cells.
- T Cell Isolation Kit II Miltenyi Biotec
- Separation efficiency was assessed using standard flow cytometry and determined to be >95% T cells.
- CD45RA+“na ⁇ ve” T cells from the CD45RO+“memory” T cells the total T cell population was incubated with anti-CD45RO microbeads (Miltenyi Biotec) for 15 minutes at +4° C. and magnetically separated according to the manufacturers instructions. The na ⁇ ve and memory T cell populations were determined to be >90% pure by flow cytometry.
- CD45RO+ memory T cells are often tissue specific and cutaneous lymphocyte antigen (CLA) is used to differentiate skin-homing T cells from gut-homing T cells expressing ⁇ 4/ ⁇ 7 on their surface.
- CLA cutaneous lymphocyte antigen
- tissue culture plates pretreated with 2.0 ⁇ g/mL anti-CD3 antibody (Southern Biotechnology).
- the cells were plated at a concentration of 2.5 ⁇ 10 6 cells/mL in tissue culture media (RPMI, 5% fetal bovine serum, L-Glutamine and Sodium Pyruvate (all Gibco)) supplemented with 2.0 ⁇ g/mL anti-CD28 (Southern Biotechnology) and placed in a +37° C. incubator. After four hours, half of the wells were harvested, cells pelleted and conditioned media frozen at ⁇ 20° C. until time of IL-31 bioassay.
- tissue culture media RPMI, 5% fetal bovine serum, L-Glutamine and Sodium Pyruvate (all Gibco)
- the CLA+ and CLA ⁇ T cell subsets were activated similarly in 48-well tissue culture plates that were pretreated with 2.0 ⁇ g/mL anti-CD3 antibody (Southern Biotechnology). The cells were activated for 16 hours or 24 hours in a +37° C. incubator at a concentration of 6.25 ⁇ 10 5 cells/mL. Samples were harvested, cells pelleted and conditioned media frozen at ⁇ 20° C. until time of IL-31 bioassay. For suboptimal activation, CLA+ T cells were cultured in plates pre-treated with 0.5 ug/ml of anti-CD3 antibody.
- BAF3 cells transfected with hIL-31RA, hOSMRbeta, and KZ134 were grown to 5 ⁇ 10 5 and 1 ⁇ 10 6 cells/mL.
- Cells were washed with assay media (RPMI 1640, 10% FBS, L-Glutamine, Sodium Pyruvate, and Pen/Strep (all Gibco)) and resuspended at 3 ⁇ 10 5 cell/mL in assay medium.
- assay media RPMI 1640, 10% FBS, L-Glutamine, Sodium Pyruvate, and Pen/Strep (all Gibco)
- hIL-31 standards were titered in duplicate from 600 pg/mL to 9.38 pg/mL in assay medium via a 100 ⁇ L/well, 1:2 serial dilution.
- Quality control standards were added in duplicate to the plate at 350 pg/mL and 35 pg/mL in 100 ⁇ L. Test samples were often diluted 1:2 or 1:4 and added in duplicate to the sample wells. 100 ⁇ L of the washed BAF3 cells were then added to each well for a final concentration of 3 ⁇ 10 4 cells/well. The plate was then incubated for 16-24 hours at +37° C. in a 5% CO 2 incubator. The plate was then centrifuged at 1200 RPM for 5 minutes, media flicked off and 25 ⁇ L/well of lysis buffer (Promega) added to each well. After 10 minutes the plate was read on a luminometer (Berthold).
- the luminometer added 40 ⁇ L/well of luciferase substrate mix (Promega) and integrated the luminescence for a period of 4 seconds. Luminescence values were exported to a spreadsheet where they were analyzed and converted into picograms of IL-31 per 10 6 cells per mL of volume. The data is summarized in Table 1.
- CD45RA+ T cells from donors #3 and #4 were activated with anti-CD3 and anti-CD28, they produced very low amounts of IL-31 (13.1 pg/10 6 cells/mL and 12.7 pg/10 6 cells/mL respectively).
- the CLA ⁇ population of T cells (which includes na ⁇ ve T cells, ⁇ 4/ ⁇ 7 gut-homing memory T cells, and tissue uncommitted T cells) from both donors generated no detectable levels of IL-31 regardless of time point or activation condition.
- the CLA+ T cells on the other hand, generated very high levels of IL-31 when stimulated with 2.0 ⁇ g/mL plate-bound anti-CD3 antibody.
- Donor #5 generated 1385.7 pg/10 6 cells/mL IL-31 by 16 hours and >1920 pg/10 6 cells/mL by 24 hours.
- Donor #6 generated 121.3 pg/10 6 cells/mL IL-31 at 16 hours and 328.9 pg/10 6 cells/mL IL-31 at 24 hours. These results clearly demonstrate that of the T cell subsets, IL-31 seems to be made specifically by cutaneous (CLA+) T cells under standard activation conditions.
- IL-31 IL-31 (pg/10 6 (pg/10 6 Donor# Cell Type Activation cells/mL) cells/mL) 6 hr 24 hr 3 CD45RA+ ⁇ CD3 + ⁇ CD28 Below Detection 13.1 3 CD45RO+ ⁇ CD3 + ⁇ CD28 8.6 110.4 4 CD45RA+ ⁇ CD3 + ⁇ CD28 6.7 12.7 4 CD45RO+ ⁇ CD3 + ⁇ CD28 11.9 145.6 16 hr 24 hr 5 CLA+ T Cells Unstimulated Below Detection Below Detection 5 CLA+ T Cells ⁇ CD3 1385.7 >1920 5 CLA ⁇ T Cells Unstimulated Below Detection Below Detection 5 CLA ⁇ T Cells ⁇ CD3 Below Detection Below Detection 6 CLA+ T Cells Unstimulated Below Detection Below Detection 6 CLA+ T Cells ⁇ CD3 121.3 328.9 6 CLA ⁇ T Cells
- mice are painted on shaved mid-back with 25 ⁇ l of 0.5% DNFB dissolved (2,4, dinitro-fluoro-benzene, Sigma, St. Louis Mo.) in acetone:olive oil (4:1) solution using a pipettor.
- a vehicle control group receives 25 ⁇ l of acetone:olive oil only.
- mice are anaesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals are measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement.
- Mice are then challenged by applying 10 ⁇ l of 0.25% DNFB in acetone:olive oil (4:1) to both sides of each ear of all mice.
- Contact hyper-sensitivity is measured at 24 h and 48 h later as the difference between the right ear (challenged) and the left ear (unchallenged). All measurements are done with an engineer's micrometer. Background values are determined by the difference in ear swelling between the challenged and unchallenged ears of naive mice.
- mice are painted on shaved mid-back with 100 ⁇ l of 0.5% FITC (fluorescein isothiocyanate) in a 1:1 solution of acetone/dibutyl phthalate (MSDS available using pipettor on days 1, 2 and 8.
- FITC fluorescein isothiocyanate
- MSDS acetone/dibutyl phthalate
- mice are anaesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals are measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement.
- Mice are challenged by applying 25 ul of 0.5% FITC (in 1:1 acetone/dibutyl phthalate) to the dorsal surface of each ear.
- Contact hyper-sensitivity is measured at 24 h and 48 h later as the difference between the right ear (challenged) and the left ear (unchallenged). All measurements are done with an engineer's micrometer. Background values are determined by the difference in ear swelling between the challenged and unchallenged ears of naive mice. Whole blood and serum for FACS and/or ELISA analysis are collected prior to sacrifice and ears are collected for histology.
- mice are painted on shaved mid-back with 25 ul of 2% oxazalone (in 4:lacetone/olive oil) using pipettor.
- mice are anaesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals are measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement.
- Mice are challenged by applying 8 ul of oxazalone to the dorsal surface of each ear.
- Contact hyper-sensitivity is measured at 24 h and 48 h later as the difference between the right ear (challenged) and the left ear (unchallenged). All measurements are done with an engineer's micrometer. Background values are determined by the difference in ear swelling between the challenged and unchallenged ears of naive mice.
- Whole blood and serum for FACS and/or ELISA analysis are collected prior to sacrifice and ears are collected for histology.
- mice Male NC/Nga mice were purchased from Charles River Laboratories, Japan. The mice were 4 weeks old on arrival and housed in SPF quarantine conditions for 4 weeks to acclimate. The mice were approximately 10-11 weeks old at the start of the antigen sensitization. Mice were anaesthetized with isofluorane and backs were shaved with electric clippers. Approximately 10 ug of Dermatophagoides pteronyssinus (Dp) (Indoor Biotechnologies, Charlottesville, Va., special order) extract was injected intradermally at the nape of the neck 3 times per week for 5 to 6 weeks until mice developed skin lesions. Control animals received 10 ul PBS intradermal injections 3 times per week.
- Dp Dermatophagoides pteronyssinus
- the Dp extract was prepared according to method by Matsuoka and colleagues. Matsuoka H., et al., Allergy: 58, 139 (2003). Briefly, 595 mg Dp lyophilized spent culture extract was dissolved in 12 mL sterile PBS (Gibco). Dp was mixed in a 50 mL Falcon tube on a shaking rocker for 30 minutes. The extract was spun for 10 minutes at 2000 rpm and the supernatant was collected and aliquoted into 1 mL cryovial tubes and stored at ⁇ 20° C.
- DO11.10 transgenic mice were bred from an in-house colony and were between 9.5 and 14 weeks old at start of antigen sensitization. Twenty-four hours prior to epicutaneous sensitization mice were anaesthetized with isofluorane and the entire trunk (back and abdomen) of mice were shaved with electric clippers. The mice were then tape stripped with Elastin surgical tape (Johnson and Johnson) on the back. One cm 2 sterile gauze patches were wetted with either 500 ug ovalbumin (Calbiochem 32467) or sterile PBS (Gibco) and adhered to left backside of mice with DuoDerm Extra Thin Dressing (ConvaTec 187932).
- the patch and dressing were then covered in a body wrap of the Elastin surgical tape so mice could not remove or destroy the patches. Patches were worn for 7 days and removed. The mice were rested for two weeks before having another round of epicutaneous sensitization. Mice received a total of three one-week sensitizations.
- mice were sensitized to antigen on day 0 by subcutaneous immunization at the base of the tail with 100 ug ovalbumin (OVA) in complete Freund's adjuvant (CFA, 50-100 ⁇ l total volume).
- OVA ovalbumin
- CFA complete Freund's adjuvant
- mice were anesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals were measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement.
- Mice were challenged intradermally with 10 ug OVA in PBS in a total volume of 10 ⁇ l into the left ear pinnae, just below the skin without hitting any veins.
- mice also received an injection of 10 ⁇ l PBS in the right ear pinnae.
- a separate control group given an i.d. injection of OVA in the ear may also be treated with topical corticosteroids as a positive control to inhibit the reaction.
- Induration the hallmark of DTH, is detectable by 18 hours after injection of sensitized antigen and is maximal by 24-48 hours. The lag in the onset of palpable induration is the reason for naming the response “delayed type.”
- IL-31 transgenic mice were tested for DTH, however, due to an increase in ear thickness in un-challenged IL-31 transgenic animals, no statistically significant difference in DTH could be determined between IL-31 Tg animals compared to wildtype controls.
- IL-31RA knockout animals were also tested in a DTH response and no significant difference in the DTH response could be observed between receptor knockout and wildtype animals.
- mice Ten week old BALB/c animals (CRL) were anaesthetized and injected with a long-lasting analgesic agent, bupranorphine hydrochloride, subcutaneously at 0.1 mg/kg before injection of 0.25 ml of 4 mg/ml solution of capsaicin in 10% ethanol+10% Tween-80 in saline subcutaneously into scruff of neck. Animals were kept anaesthetized for at least 30 min following neurotoxin treatment. Forty-eight hours later, 14-day osmotic pumps were implanted subcutaneously for continuous delivery of 20 ug/day of IL-31 for 14 days.
- analgesic agent bupranorphine hydrochloride
- mice treated with capsaicin prior to IL-31 delivery showed both a delay in incidence of scratching and hairloss and a lower score in the intensity of scratching and hairloss over the six days of the experiment.
- IL-31 does induce some neuronal component that contributes to the alopecia and pruritis induced by IL-31. Therefore, neutralization of IL-31 may decrease the incidence and intensity of itch, and therefore dermatitis, in patients suffering from skin disorders that involve itch.
- mice that are homozygous null for the Tac1 gene express no detectible substance P or neurokinin A. These mice have significantly reduced nociceptive pain responses to moderate to intense stimuli and are therefore a useful tool for studying the contribution of tachykinin peptides to pain/itch processing and inflammatory disease states.
- mice Normal female BALB/c mice (CRL) approximately 8 to 12 weeks old were implanted subcutaneously with 14-day osmotic pumps (Alzet, #2002) delivering 1 ug/day mIL-31.
- Groups of mice received intraperitoneal (i.p.) injections of rat anti-mouse IL-31 monoclonal antibody 10 mg/kg (200 ug/mouse) twice weekly starting 1 week prior to IL-31 delivery.
- Control groups of mice received i.p. injections of vehicle (PBS/0.1% BSA) with the identical dosing schedules.
- mice treated with rat anti-mIL-31 mAb had a delay in onset of symptoms of approximately 5 to 7 days and a lower overall score for alopecia and pruritis. All groups of mAb treated mice (regardless of dose frequency or concentration) developed alopecia and pruritis similar to control mice by 13 day of the study. These data suggest that neutralization of IL-31 can delay the onset of the scratch/hairloss response induced by IL-31.
- IHC Immunohistochemical Staining of IL-31 in Skin Lesions from Uninvolved Psoriatic, and Atopic Dermatitis
- Uninvolved psoriatic, atopic dermatitis and normal skin were tested for the IL-31 ligand by IHC.
- Positive control cells consisted of BHK cells transfected with IL-31.
- Negative controls performed included: (1) un-transfected BHK cells, (2) staining representative tissues and cells with protein A purified Normal Rabbit serum and detecting antibody binding as usual.
- Antibody reagent was E5758 (Rabbit anti-huIL-31 CEE, Aff. Purified at 1.0 mg/ml).
- Control cells included C02-6020: BHK cells expressing zcytor17 Lig hu-CEE/21, and a BHK wild type.
- Tissues tested included acute atopic dermatitis skin samples, chronic atopic dermatitis skin samples, unaffected area skin samples, and normal control skin samples and other in-house control samples.
- the cells and tissues described above were fixed overnight in 10% NBF and embedded in paraffin using standard techniques.
- Tissues washed twice in TBST, and then incubated 45 minutes in biotinylated Goat anti-Rabbit Ab, 750 ng/ml in PBSB (catalog # BA-1000, Vector Labs). Slides washed twice in TBST. Vectastain Elite ABC Reagent (catalog# PK-7100, Vector Labs) was incubated for 45 minutes. Slides washed twice in TBST. Signals were developed with DAB+ (catalog# K-3468, DakoCytomation) for 10 minutes at room temperature. Tissue slides were then counterstained in hematoxylin (catalog# H-3401 Vector Labs), dehydrated and coverslipped in VectorMount (catalog# H-5000, Vector Labs).
- BHK cells transfected with IL-31 was positively stained with IL-31 antibody E5758 while un-transfected cells was negative for this antibody. The same transfected and un-transfected cells were negative with anti-rabbit sera.
- the staining pattern for IL31 in the AD skin samples is identical to that of psoriasis skins reported previously: keratinocyte and CD3 positive T-cells stained negative for IL31.
- a weak but rather uniform staining of the epithelial cells in the secretory portion of the sweat glands was present, but a strong signal was observed in the inner layer of epithelium in the duct portion. Sebaceous gland was positive for IL31. There was no difference in the IL31 staining between AD and normal skin.
- Immunohistochemical (IHC) staining of uninvolved psoriatic, atopic dermatitis and normal skin showed strong staining of IL-31 in the holocrine secretion of the sebaceous glands.
- the sebaceous glands originate as an epithelial bud from the outer root sheath of hair follicles.
- staining of IL-31 was observed in the epithelial cells in the secretory portion of the sweat glands and a strong signal in the inner layer of epithelium was observed in the duct portion of sweat glands.
- IL-31RA Uninvolved psoriatic, atopic dermatitis and normal skin were tested for the IL-31RA by IHC.
- Positive control cells consisted of BHK cells dual transfected with IL-31RA and OSMR.
- Antibody reagent was E6292 (Rabbit anti-huIL-31RAs-CEE v.4 at 1.33 mg/ml).
- Control cells included C02-5117 BHK cells expressing human IL-31RA and human OSMR (Total cells in the pellet: 3.9 ⁇ 10 6 , vitality was >90%) and C04-1587: BHK wild type (Total cells in the pellet: 5 ⁇ 10 6 ).
- the cells and tissues described above were fixed overnight in 10% NBF and embedded in paraffin using standard techniques.
- Tissues were washed twice in TBST, and then incubated 45 minutes in biotinylated Goat anti-Rabbit Ab, 750 ng/ml in PBSB (catalog # BA-1000, Vector Labs). Slides were washed twice in TBST. Vectastain Elite ABC Reagent (catalog# PK-7100, Vector Labs) was incubated for 45 minutes. Slides were washed twice in TBST. Signals were developed with DAB+(catalog# K-3468, DakoCytomation) for 10 minutes at room temperature. Tissue slides were then counterstained in hematoxylin (catalog# H-3401 Vector Labs), dehydrated and coverslipped in VectorMount (catalog# H-5000, Vector Labs).
- AD skins may have more CLA positive cells than that of the normal or UAD samples.
- IL-31RA was also expressed in the epithelial cells of eccrine sweat glands with the cuboidal epithelial cells in the secretory portion of the eccrine glands demonstrating slightly higher level of IL-31RA protein compared to the duct portion.
- IL-31RA is expressed by epidermal keratinocytes from both control volunteers and AD patients.
- the levels of IL-31RA expressed on keratinocytes from AD skin biopsies were higher than the levels observed in skin biopsies from normal controls, indicating a potential for increased responsiveness to IL-31 in the context of AD.
- IL-31RA was also found expressed on a subset of perivascular infiltrating cells present in skin biopsies from AD patients but was not present in control skin biopsies. These IL-31RA+ cells were recognized by an antibody specific for the tissue macrophage marker CD68, indicating these cells were skin-infiltrating tissue macrophages.
- the presence of skin infiltrating T cells is a distinguishing feature in skin biopsies from AD patients compared to normal individuals. Since IL-31 is a T cell associated cytokine, the expression of IL-31 in skin-infiltrating T cells in tissue biopsies from AD patients was examined. First, the presence of increased numbers of CD3+ T cells in skin tissue biopsies from AD patients compared to normal individuals was confirmed by IHC. See Table 2. Next, laser capture microscopy was used to specifically isolate skin infiltrating cells for analysis of IL-31 mRNA by RT-PCR. IL-31 mRNA was expressed by skin infiltrating cells from acute AD patients. In normal tissues, infiltrating cells are not normally found and therefore could not be tested.
- the epidermal keratinocyte layer which is present in both AD and normal skin, was analyzed for IL-31 mRNA expression and lower levels of IL-31 mRNA were found in normal samples compared to the epidermal keratinocyte layer of AD samples.
- Semi-quantitative analysis of IL-31 mRNA expression compared to an internal control gene (HPRT) showed that although IL-31 mRNA levels were not significantly different between AD and normal samples, there was a trend towards higher IL-31 expression in skin from AD patients.
- IL-31 is Produced by Memory T Cells with a Skin-Homing Phenotype
- CD45RO+ T cells in the skin which express IL-31 mRNA, express the skin-homing marker cutaneous lymphocyte antigen (CLA).
- CLA cutaneous lymphocyte antigen
- CLA+ and CLA ⁇ T cells were isolated from peripheral blood of patients diagnosed with AD and control volunteers and compared IL-31 mRNA and protein levels following anti-CD3 plus anti-CD28 stimulation.
- Our results indicate that IL-31 mRNA was significantly elevated in CLA+ T cells from both AD and normal individuals at both 4 h (p0.0087 and p0.0022 CLA+ compared to CLA ⁇ for AD and normal, respectively) and 24 h (p0.0022 CLA+ compared to CLA ⁇ for both AD and normal samples) post stimulation.
- IL-31 protein levels in culture supernatants confirmed that IL-31 was produced predominantly by CLA+ T cells as there was no detectible IL-31 in culture supernatants from CLA ⁇ T cells from both AD and control individuals. There were no significant differences in IL-31 levels between AD and normal patients.
- peripheral blood T cells that express other tissue-specific homing markers, such as the gut-specific homing marker ⁇ 4 ⁇ 7, from normal volunteers.
- CLA+ T cells from AD patients are reported to exist in a more activated state compared to cells from normal individuals. Consequently, the threshold of stimulation required for the production of IL-31 by CLA+ T cells may differ between dermatitis patients and control subjects.
- AD patients showed a trend towards higher IL-31 levels compared to psoriasis patients and normal individuals following suboptimal stimulation with anti-CD3. Since more CLA+ T cells are localized in skin of AD patients as compared to normal individuals, our studies suggest that there is an increased potential for IL-31 activity in the AD skin micro-environment. Thus, this study may suggest a subpopulation of AD patients, which have more activated CLA+ T cells producing IL-31.
- mice Six-week old male NC/Nga mice (CRL Japan) were sensitized intradermally with 50 ⁇ g dust mite extract ( D. pteronyssinus , Indoor Biotechnologies) three times a week on the back and scored for AD-like lesions. After 5 weeks of sensitization the mice were euthanized and the right ears were excised and placed into a single well of a 48-well culture dish (Corning) supplemented with RPMI+2% FBS (GIBCO Invitrogen). Plates were placed in 5% CO2 humidity controlled incubators. Supernatants were collected after 24 hours and frozen at ⁇ 20° C. until further analysis.
- 50 ⁇ g dust mite extract D. pteronyssinus , Indoor Biotechnologies
- mice Twelve-week old female NC/Nga mice (CRL Japan) were sensitized intradermally with 10 ⁇ g SEB (Toxin Technology) in the ear and on the back three times per week. The mice were scored for AD-like lesions. After 5 weeks of sensitization the mice were euthanized and 6 mm biopsy punches were taken from the injected ear of each mouse and placed into a single well of a 48-well culture dish supplemented with RPMI+2% FBS. Plates were placed in 5% CO2 humidity controlled incubators. Supernatants were collected after 24 hours and frozen at ⁇ 20° C. until further analysis.
- SEB Toxin Technology
- mice in both studies were treated with either a rat anti-mouse IL-31 monoclonal antibody at 10 mg/kg or vehicle, intraperitoneally two times each week starting after 1 to 2 weeks of sensitization.
- TARC and MDC concentrations in the 24-hour supernatant samples were measured by conventional ELISA (R&D Systems).
- TARC and MDC concentrations were lower in ear supernatants from anti-IL-31 treated mice compared to control mice in both studies, however, these results were not statistically significant when analyzed by ANOVA, probably due to small sample size. When the data from both experiments is combined and analyzed there is a statistically significant difference between treated groups.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/829,711, filed Aug. 19, 2015, which is a divisional of U.S. patent application Ser. No. 12/986,707, filed Jan. 7, 2011, now U.S. Pat. No. 9,139,651, which is a divisional of U.S. application Ser. No. 12/404,162, filed Mar. 13, 2009, now U.S. Pat. No. 7,871,618, which is a continuation of U.S. application Ser. No. 11/353,451, filed Feb. 14, 2006, abandoned, which claims the benefit of U.S. Patent Application Ser. No. 60/716,761, filed Sep. 13, 2005, U.S. Patent Application Ser. No. 60/694,867, filed Jun. 29, 2005, and U.S. Patent Application Ser. No. 60/653,283, filed Feb. 14, 2005, all of which are herein incorporated by reference.
- The skin plays an important role in the immune system and consists of layers. The epidermis is a surface layer. Underneath the epidermis is the dermis, a layer of connective tissue. Underneath the dermis, is the hypodermis, a layer of large amounts of adipose tissue. Circulating T lymphocytes migrate to the skin under normal and inflammatory conditions. The cutaneous lymphocyte antigen (CLA) is considered a homing receptor for T cells with tropism for the skin. Santamaria-Babi, L., Eur. J. Dermatol. 14:13-18, 2004. CLA is a carbohydrate structure which is expressed on memory T cells as an epitope of the single cell-surface protein named P-selectin glycoprotein ligand-1 (PSGL-1) and facilitates binding of T cells to E-selectin, an inducible adhesion molecule expressed on vascular endothelium. See Fuhlbrigge R C, et al., Nature 1997; 389:978-81.
- Several diseases of the skin are known to express high levels of CLA+ T cells, including atopic dermatitis, contact dermatitis, drug-induced allergic reactions, skin-tropic viruses and viral associated pruritis, vitiligo, cutaneous T cell lymphoma, alopecia aerata, acne rosacea, acne vulgaris, prurigo nodularis, and bullous pemphigoid. There is a need to treat such skin T cell mediated diseases.
- The demonstrated in vivo activities of the cytokine family illustrate the enormous clinical potential of, and need for, other cytokines, cytokine agonists, and cytokine antagonists. The present invention addresses these needs by providing a method of treating such diseases with IL-31RA antagonists, e.g., IL-31RA soluble receptor or neutralizing IL-31RA monoclonal antibody or fragment, a receptor for the newly identified IL-31 cytokine. IL-31, when over-expressed in mice, results in dermatitis-like symptoms. Both skin-homing T cells and epidermal keratinocytes have been implicated in the pathology of skin diseases in humans.
- The present invention provides such polypeptides for these and other uses that should be apparent to those skilled in the art from the teachings herein.
- Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:
- Unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one.
- The term “affinity tag” is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952-4, 1985), substance P, Flag™ peptide (Hopp et al., Biotechnology 6:1204-10, 1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2: 95-107, 1991. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, N.J.).
- The term “allelic variant” is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.
- The terms “amino-terminal” and “carboxyl-terminal” are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.
- The term “complement/anti-complement pair” denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of <109 M−1.
- The term “complements of a polynucleotide molecule” denotes a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5′ ATGCACGGG 3′ is complementary to 5′ CCCGTGCAT 3′.
- The term “contig” denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to “overlap” a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5′-ATGGCTTAGCTT-3′ (SEQ ID NO:18) are 5′-TAGCTTgagtct-3′ (SEQ ID NO:19) and 3′-gtcgacTACCGA-5′ (SEQ ID NO:20).
- The term “degenerate nucleotide sequence” denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).
- The term “expression vector” is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
- The term “isolated”, when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5′ and 3′ untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).
- An “isolated” polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term “isolated” does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.
- The term “operably linked”, when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.
- The term “ortholog” denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.
- “Paralogs” are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, α-globin, β-globin, and myoglobin are paralogs of each other.
- A “polynucleotide” is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5′ to the 3′ end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated “bp”), nucleotides (“nt”), or kilobases (“kb”). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term “base pairs”. It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired.
- A “polypeptide” is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides”.
- The term “promoter” is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5′ non-coding regions of genes.
- A “protein” is a macromolecule comprising one or more polypeptide chains A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
- The term “receptor” denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell. Membrane-bound receptors are characterized by a multi-peptide structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).
- The term “secretory signal sequence” denotes a DNA sequence that encodes a polypeptide (a “secretory peptide”) that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.
- A “soluble receptor” is a receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides that lack transmembrane and cytoplasmic domains. Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate, or immunoglobulin constant region sequences. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis. Soluble receptor polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively.
- The term “splice variant” is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.
- Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as “about” X or “approximately” X, the stated value of X will be understood to be accurate to ±10%.
- All references cited herein are incorporated by reference in their entirety.
- The present invention provides novel methods of using IL-31RA antagonists in detection, diagnosis, and treatment of diseases, in particular, diseases that have a high correlation of cutaneous lymphocyte antigen (CLA). The present invention is based in part upon the discovery that a previously identified cytokine, IL-31 is expressed by skin-homing T cells, but not gut-homing T cells.
- IL-31 is a recently discovered protein having the structure of a four-helical-bundle cytokine. This cytokine was previously identified as IL-31 and is fully described in U.S. patent application Ser. No. 10/352,554, filed Jan. 21, 2003. See published U.S. Patent Application No. 2003-0224487, and PCT application WO 03/060090, all herein incorporated by reference. See also, Dillon, et al., Nature Immunol. 5:752-760, 2004. IL-31 is a ligand with high specificity for the receptor IL-31RA and at least one additional subunit comprising OncostatinM receptor beta (OSMRbeta). The native polynucleotide and polypeptide sequences for human IL-31 are shown in SEQ ID NOs:1 and 2, respectively. The native polynucleotide and polypeptide sequences for mouse IL-31 are shown in SEQ ID NOs:3 and 4, respectively.
- As used herein the term, IL-31 also means and is interchangeably referred to as Zcytor17lig, and IL-31RA also means and is interchangeably referred to as Zcytor17, as used in U.S. patent publication number 20030224487 (herein incorporated by reference), as shown above. The heterodimeric receptor for IL-31 was also described in 20030224487 as comprising zcytor17 (HUGO name, IL-31RA) and with at least one additional subunit comprising OncostatinM receptor beta (OSMRbeta).
- The native polynucleotide and polypeptide sequences for the “long” form of IL-31RA are shown in SEQ ID NOs:5 and 6, respectively. The native polynucleotide and polypeptide sequences for the “short” form of IL-31RA are shown in SEQ ID NOs:7 and 8, respectively. Additionally, truncated forms of IL-31RA polypeptide appear to be naturally expressed. Both forms encode soluble IL-31RA receptors. The “long” soluble IL-31RA polynucleotide and polypeptide sequences are shown in SEQ ID NOs:9 and 10, respectively. The “short” soluble IL-31RA polynucleotide and polypeptide sequences are shown in SEQ ID NOs:11 and 12, respectively. The native polynucleotide and polypeptide sequences for mouse IL-31RA are shown in SEQ ID NOs:13 and 14, respectively. The native polynucleotide and polypeptide sequences for human OSMRbeta are shown in SEQ ID NOs:15 and 16, respectively. See PCT applications WO 02/00721 and WO 04/003140, both of which are incorporated by reference.
- The secretory signal sequence of IL-31 is comprised of amino acid residues 1 (Met) to 23 (Ala), and the mature polypeptide is comprised of amino acid residues 24 (Ser) to 164 (Thr) as shown in SEQ ID NO:2. Further N-terminal sequencing analysis of purified IL-31 from 293T cells showed an N-terminus at residue 27 (Leu) as shown in SEQ ID NO:2, with the mature polypeptide comprised of amino acid residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2.
- Cytokine receptor subunits are characterized by a multi-domain structure comprising an extracellular domain, a transmembrane domain that anchors the polypeptide in the cell membrane, and an intracellular domain. The extracellular domain may be a ligand-binding domain, and the intracellular domain may be an effector domain involved in signal transduction, although ligand-binding and effector functions may reside on separate subunits of a multimeric receptor. The domains and structural features of the IL-31RA polypeptides (zcytor17) are further described below.
- Analysis of the IL-31RA polypeptide encoded by the DNA sequence of SEQ ID NO:5 revealed an open reading frame encoding 732 amino acids (SEQ ID NO:6) comprising a predicted secretory signal peptide of 19 amino acid residues (residue 1 (Met) to residue 19 (Ala) of SEQ ID NO:6), and a mature polypeptide of 713 amino acids (residue 20 (Ala) to residue 732 (Val) of SEQ ID NO:6). Analysis of the IL-31RA polypeptide encoded by the DNA sequence of SEQ ID NO:7 revealed an open reading frame encoding 662 amino acids (SEQ ID NO:8) comprising a predicted secretory signal peptide of 32 amino acid residues (residue 1 (Met) to residue 32 (Ala) of SEQ ID NO:8), and a mature polypeptide of 630 amino acids (residue 33 (Ala) to residue 662 (Ile) of SEQ ID NO:8). In addition to the WSXWS motif (SEQ ID NO:17) (corresponding to residues 211 to 215 of SEQ ID NO:6; and residues 224 to 228 of SEQ ID NO:8), the receptor comprises an extracellular domain (residues 20 (Ala) to 519 (Glu) of SEQ ID NO:6; residues 33 (Ala) to 532 (Glu) of SEQ ID NO:8) which includes a cytokine-binding domain of approximately 200 amino acid residues (residues 20 (Ala) to 227 (Pro) of SEQ ID NO:6; residues 33 (Ala) to 240 (Pro) of SEQ ID NO:8); a domain linker (residues 122 (Thr) to 125 (Pro) of SEQ ID NO:6; residues 135 (Thr) to 138 (Pro) of SEQ ID NO:8); a penultimate strand region (residues 194 (Phe) to 202 (Arg) of SEQ ID NO:6; residues 207 (Phe) to 215 (Arg) of SEQ ID NO:8); a fibronectin type III domain (residues 228 (Cys) to 519 (Glu) of SEQ ID NO:6; residues 241 (Cys) to 532 (Glu) of SEQ ID NO:8); a transmembrane domain (residues 520 (Ile) to 543 (Leu) of SEQ ID NO:6; residues 533 (Ile) to 556 (Leu) of SEQ ID NO:8); complete intracellular signaling domain (residues 544 (Lys) to 732 (Val) of SEQ ID NO:6; and residues 557 (Lys) to 662 (Ile) of SEQ ID NO:8) which contains a “Box I” signaling site (residues 554 (Trp) to 560 (Pro) of SEQ ID NO:6; residues 567 (Trp) to 573 (Pro) of SEQ ID NO:8), and a “Box II” signaling site (residues 617 (Gln) to 620 (Phe) of SEQ ID NO:6; residues 630 (Gln) to 633 (Phe) of SEQ ID NO:8). Those skilled in the art will recognize that these domain boundaries are approximate, and are based on alignments with known proteins and predictions of protein folding. In addition to these domains, conserved receptor features in the encoded receptor include (as shown in SEQ ID NO:6) a conserved Cys residue at position 30 (position 43 as shown in SEQ ID NO:8), CXW motif (wherein X is any amino acid) at positions 40-42 of SEQ ID NO:6 (positions 53-55 as shown in SEQ ID NO:8), Trp residue at position 170 of SEQ ID NO:6 (position 183 as shown in SEQ ID NO:8), and a conserved Arg residue at position 202 of SEQ ID NO:6 (position 215 as shown in SEQ ID NO:8). The corresponding polynucleotides encoding the IL-31RA polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NOs:5 and 7.
- Moreover, truncated forms of the IL-31RA polypeptide appear to be naturally expressed. Both forms encode soluble zcytor17 receptors. A polynucleotide encoding a “long-form” of the soluble zcytor17 receptor, truncated within the fibronectin type III domain, is shown in SEQ ID NO:9 and the corresponding polypeptide is shown in SEQ ID NO:10. This truncated form encodes residues 1 (Met) through 324 (Lys) of SEQ ID NO:6, and thus comprises an intact signal sequence, WSXWS (SEQ ID NO:17) motif, linker, cytokine binding domain, penultimate strand, and conserved, Cys, CXW motif, Trp and Arg residues as described above. A polynucleotide encoding a “short-form” of the soluble IL-31RA receptor, truncated at the end of the cytokine binding domain is shown in SEQ ID NO:11 and the corresponding polypeptide is shown in SEQ ID NO:12. This truncated form encodes a 239 residue polypeptide that is identical to residues 1 (Met) through 225 (Glu) of SEQ ID NO:6 and then diverges, and thus comprises an intact signal sequence, WSXWS (SEQ ID NO:17) motif, linker, cytokine binding domain, penultimate strand, and conserved, Cys, CXW motif, Trp and Arg residues as described above.
- Both skin-homing T cells and epidermal keratinocytes have been implicated in the pathology of skin diseases in humans. As shown herein, IL-31 mRNA and protein expression is restricted to the skin-homing CLA+ T cell population in both atopic dermatitis (AD) patients and normal individuals, while analysis of the receptor for IL-31, IL-31RA, by immunohistochemistry (IHC) suggests slightly higher levels of IL-31RA expression on skin keratinocytes in skin biopsies from acute and chronic AD sufferers compared to normal individuals.
- When over-expressed in mice, IL-31 results in pruritus and the development of skin dermatitis resembling human atopic dermatitis (AD) Immunohistochemistry (IHC) studies shown herein show that IL-31RA protein was expressed by skin keratinocytes and infiltrating macrophages in skin biopsies from AD patients. Comparisons between AD patients and normal individuals suggested that IL-31RA was expressed at higher levels on epidermal keratinocytes in the AD samples. Skin cell infiltrates, which were present at greater numbers in skin of AD patients compared to normal individuals, expressed IL-31 mRNA. Histomorphometric analysis of these cells suggested a lymphocytic lineage with the majority of cells staining positive for cutaneous lymphocyte antigen (CLA) and CD3, demonstrating that skin-homing T cells in skin express IL-31 mRNA. Upon analysis of peripheral blood T cells for IL-31, IL-31 mRNA and protein expression is largely restricted to CD45RO+ CLA+ skin-homing T cells in AD and normal volunteers. Moreover, circulating CLA+ T cells from AD patients are capable of producing higher levels of IL-31 compared to CLA+ T cells from normal individuals, though there is large variability between patient samples. These results provide strong evidence that IL-31 expression is associated with atopic dermatitis and may contribute to the development of AD skin inflammation and pruritus.
- As shown herein, IL-31 is produced both locally in the skin and by skin infiltrating cells. Local production of cytokines in tissues by T cells is thought to be a key mechanism for disease pathogenesis in AD and increased numbers of T cells both in circulation and in skin is thought to correlate with disease.
- Although both AD patients and normal controls have circulating CLA+ T cells that express IL-31 upon activation, CLA+ T cells from AD patients are reported to exist in a more activated state compared to cells from normal individuals. See Akdis M, J Immunol., 159:4611-4619, 1997. Consequently, the threshold of stimulation required for the production of IL-31 by CLA+ T cells may differ between dermatitis patients and control subjects. As shown herein, circulating CLA+ T cells from AD patients after 24 hours of stimulation with sub-optimal concentrations of anti-CD3 in the absence of anti-CD28 have the capacity to produce higher levels of IL-31 compared to cells from normal individuals. Due to the variability in IL-31 levels produced by CLA+ T cells from individual AD patients, there was no significant difference in the average IL-31 production from circulating CLA+ T cells of AD and normal individuals. Nevertheless, since more CLA+ T cells are localized in skin of AD patients, as compared to normal individuals, there is an increased potential for IL-31 activity in the AD skin micro-environment.
- Example 1 demonstrates that circulating CLA+ T cells from some AD patients produce higher levels of IL-31 compared to cells from normal individuals. The detection of IL-31 in patients of such a subpopulation using the bioassay provided herein, or with any assay that detects IL-31 produced by circulating T cells in the blood, may be useful to determine if an IL-31 antagonist will be useful as treatment for diseases wherein the presence of IL-31 causes inflammation.
- A cell line that is dependent on the OSMRbeta and IL-31RA linked pathway for survival and growth in the absence of other growth factors can be used to measure the activity of IL-31. Such growth factor-dependent cell lines include BaF3, FDC-P1, and MO7e. For information on the BaF3 cell line, see Palacios and Steinmetz, (Cell, 41:727-734, 1985) and Mathey-Prevot et al., (Mol. Cell. Biol., 6:4133-4135, 1986). For information on the FDC-P1 cell line, see Hapel et al. (Blood, 64:786-790, 1984). For information on the MO7e cell line, see Kiss et al., (Leukemia, 7:235-240, 1993).
- The amino acid sequence for the OSMRbeta, and IL-31RA receptors indicated that the encoded receptors belonged to the Class I cytokine receptor subfamily that includes, but is not limited to, the receptors for IL-2, IL-4, IL-7, Lif, IL-12, IL-15, EPO, TPO, GM-CSF and G-CSF (for a review see, Cosman, “The Hematopoietin Receptor Superfamily” in Cytokine 5(2): 95-106, 1993). The IL-31RA receptor is fully described in PCT Patent Application No. US01/20484 (WIPO publication No. WO 02/00721). Analysis of the tissue distribution of the mRNA of the IL-31RA receptor revealed expression in activated CD4+ and CD8+ T-cell subsets, CD14+ monocytes, and weaker expression in CD19+ B-cells. Moreover, the mRNA was present in both resting or activated monocytic cell lines THP-1 (ATCC No. TIB-202), U937 (ATCC No. CRL-1593.2) and HL60 (ATCC No. CCL-240).
- Antigenic epitope-bearing peptides and polypeptides preferably contain at least four to ten amino acids, at least ten to fourteen amino acids, or about fourteen to about thirty amino acids of the extracellular domains of SEQ ID NO:6 or SEQ ID NO:8. Such epitope-bearing peptides and polypeptides can be produced by fragmenting the extracellular domain of IL-31RA polypeptide, or by chemical peptide synthesis, as described herein. Moreover, epitopes can be selected by phage display of random peptide libraries (see, for example, Lane and Stephen, Curr. Opin. Immunol. 5:268 (1993); and Cortese et al., Curr. Opin. Biotechnol. 7:616 (1996)). Standard methods for identifying epitopes and producing antibodies from small peptides that comprise an epitope are described, for example, by Mole, “Epitope Mapping,” in Methods in Molecular Biology, Vol. 10, Manson (ed.), pages 105-116 (The Humana Press, Inc. 1992); Price, “Production and Characterization of Synthetic Peptide-Derived Antibodies,” in Monoclonal Antibodies: Production, Engineering, and Clinical Application, Ritter and Ladyman (eds.), pages 60-84 (Cambridge University Press 1995), and Coligan et al. (eds.), Current Protocols in Immunology, pages 9.3.1-9.3.5 and pages 9.4.1-9.4.11 (John Wiley & Sons 1997).
- The IL-31RA polypeptides of the present invention, including full-length polypeptides, functional fragments, and fusion polypeptides, can be produced, purified and refolded by methods well-known in the art and as described in PCT applications WO 02/00721 and WO 04/003140. It is preferred to purify the polypeptides of the present invention to 80% purity, more preferably to 90% purity, even more preferably 95% purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.
- The present invention provides methods for using IL-31RA antagonists, including anti-IL-31RA antibodies and fragments, soluble IL-31RA receptors, and soluble IL-31RA/OSMRbeta receptors for reducing, inhibiting, or preventing inflammation in cell microenvironments where one or more cells in the microenvironment is/are T cells that are positive for the cutaneous lymphocyte antigen.
- Antibodies from an immune response generated by inoculation of an animal with IL-31RA antigens, e.g., extracellular domain of SEQ ID NO:6 or a portion thereof, such as ligand binding domain) can be isolated and purified are known in the art and are described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., 1989; and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, Fla., 1982.
- As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a IL-31RA polypeptide or a fragment thereof. The immunogenicity of an IL-31RA polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of IL-31RA or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is “hapten-like”, such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.
- As used herein, the term “antibodies” includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as Fab fragment, Fab′ fragment, F(ab′)2 fragment, single chain Fv (scFv) proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally “cloaking” them with a human-like surface by replacement of exposed residues, wherein the result is a “veneered” antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced. Moreover, human antibodies can be produced in transgenic, non-human animals that have been engineered to contain human immunoglobulin genes as disclosed in WIPO Publication No. WO 98/24893. It is preferred that the endogenous immunoglobulin genes in these animals be inactivated or eliminated, such as by homologous recombination.
- Antibodies are considered to be specifically binding if: 1) they exhibit a threshold level of binding activity, and 2) they do not significantly cross-react with related polypeptide molecules. A threshold level of binding is determined if anti-IL-31RA antibodies herein bind to an IL-31RA polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non-IL-31RA) polypeptide. It is preferred that the antibodies exhibit a binding affinity (Ka) of 106 M−1 or greater, preferably 107 M−1 or greater, more preferably 108 M−1 or greater, and most preferably 109 M−1 or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672, 1949).
- The present invention provides a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of an anti-IL-31RA antibody or fragment to the patient, wherein the anti-IL-31RA antibody or fragment binds with amino acid residues 20-519 of SEQ ID NO:6 or portion thereof, or amino acid residues 33-532 of SEQ ID NO:8 or portion thereof, and wherein the anti-IL-31RA antibody or fragment prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus. The anti-IL-31RA antibody may optionally be a polyclonal antibody or a neutralizing monoclonal antibody (the present invention also provides for a hybridoma for producing the neutralizing IL-31RA monoclonal antibody). The anti-IL-31RA antibody fragment may optionally be a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, single chain Fv (scFV), dual specific antibody, domain antibody, or bispecific antibody. The anti-IL-31RA antibody or fragment may bind with amino acid residues 20-277 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8. The anti-IL-31RA antibody or fragment may bind with about 4-10 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8. The anti-IL-31RA antibody or fragment may bind with about 10-14 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8. The anti-IL-31RA antibody or fragment may bind with about 14-30 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8. The anti-IL-31 antibody or fragment may be further conjugated to a polyethylene glycol or to human serum albumin.
- The present invention also provides for a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of a soluble IL-31RA receptor to the patient, wherein the soluble IL-31RA receptor binds with an IL-31 polypeptide consisting of amino acid residues 1-164 SEQ ID NO:2, and wherein the soluble IL-31RA receptor prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus. The soluble IL-31RA receptor may comprise amino acid residues 20-519 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8, amino acid residues 1-324 of SEQ ID NO:10, or amino acid residues 1-239 of SEQ ID NO:12. The soluble IL-31RA receptor may be further conjugated to the Fc region of the various immunoglobulins (IgG, IgA, IgD, IgM or IgE). Optionally, the soluble IL-31RA receptor may be an IL-31RA homodimer or an IL-31RA/OSMRbeta heterodimer. The soluble IL-31RA receptor may bind with an IL-31 polypeptide comprising, consisting essentially of, consisting of amino acid residues 24-164 of SEQ ID NO:2 or 27-164 of SEQ ID NO:2. The soluble IL-31RA receptor may be further conjugated to a polyethylene glycol or to human serum albumin.
- The present invention also provides isolated IL-31RA encoding nucleic acid molecules that can hybridize under stringent conditions to nucleic acid molecules having the nucleotide sequence of nucleotides 58-1557 of SEQ ID NO:5 or nucleotides 97-1596 SEQ ID NO:7, or to nucleic acid molecules having a nucleotide sequence complementary to nucleotides 58-1557 of SEQ ID NO:5 or to nucleotides 97-1596 SEQ ID NO:7. In general, stringent conditions are selected to be about 5*C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
- A pair of nucleic acid molecules, such as DNA-DNA, RNA-RNA and DNA-RNA, can hybridize if the nucleotide sequences have some degree of complementarity. Hybrids can tolerate mismatched base pairs in the double helix, but the stability of the hybrid is influenced by the degree of mismatch. The Tm of the mismatched hybrid decreases by 1° C. for every 1-1.5% base pair mismatch. Varying the stringency of the hybridization conditions allows control over the degree of mismatch that will be present in the hybrid. The degree of stringency increases as the hybridization temperature increases and the ionic strength of the hybridization buffer decreases.
- It is well within the abilities of one skilled in the art to adapt these conditions for use with a particular polynucleotide hybrid. The Tm for a specific target sequence is the temperature (under defined conditions) at which 50% of the target sequence will hybridize to a perfectly matched probe sequence. Those conditions which influence the Tm include, the size and base pair content of the polynucleotide probe, the ionic strength of the hybridization solution, and the presence of destabilizing agents in the hybridization solution. Numerous equations for calculating Tm are known in the art, and are specific for DNA, RNA and DNA-RNA hybrids and polynucleotide probe sequences of varying length (see, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Press 1989); Ausubel et al., (eds.), Current Protocols in Molecular Biology (John Wiley and Sons, Inc. 1987); Berger and Kimmel (eds.), Guide to Molecular Cloning Techniques, (Academic Press, Inc. 1987); and Wetmur, Crit. Rev. Biochem. Mol. Biol. 26:227 (1990)). Sequence analysis software such as OLIGO 6.0 (LSR; Long Lake, Minn.) and Primer Premier 4.0 (Premier Biosoft International; Palo Alto, Calif.), as well as sites on the Internet, are available tools for analyzing a given sequence and calculating Tm based on user defined criteria. Such programs can also analyze a given sequence under defined conditions and identify suitable probe sequences. Typically, hybridization of longer polynucleotide sequences, >50 base pairs, is performed at temperatures of about 20-25° C. below the calculated Tm. For smaller probes, <50 base pairs, hybridization is typically carried out at the Tm or 5-10° C. below the calculated Tm. This allows for the maximum rate of hybridization for DNA-DNA and DNA-RNA hybrids.
- Following hybridization, the nucleic acid molecules can be washed to remove non-hybridized nucleic acid molecules under stringent conditions, or under highly stringent conditions. Typical stringent washing conditions include washing in a solution of 0.5×-2×SSC with 0.1% sodium dodecyl sulfate (SDS) at 55-65° C. That is, nucleic acid molecules encoding a variant IL-31RA polypeptide hybridize with a nucleic acid molecule having the nucleotide sequence of nucleotides 58-1557 of SEQ ID NO:5 (or its complement) or nucleotides 97-1596 SEQ ID NO:7 (or its complement) under stringent washing conditions, in which the wash stringency is equivalent to 0.5×-2×SSC with 0.1% SDS at 55-65° C., including 0.5×SSC with 0.1% SDS at 55° C., or 2×SSC with 0.1% SDS at 65° C. One of skill in the art can readily devise equivalent conditions, for example, by substituting SSPE for SSC in the wash solution.
- Typical highly stringent washing conditions include washing in a solution of 0.1×-0.2×SSC with 0.1% sodium dodecyl sulfate (SDS) at 50-65° C. In other words, nucleic acid molecules encoding a variant IL-31RA polypeptide hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1×-0.2×SSC with 0.1% SDS at 50-65° C., including 0.1×SSC with 0.1% SDS at 50° C., or 0.2×SSC with 0.1% SDS at 65° C.
- The present invention also provides isolated IL-31RA polypeptides that have a substantially similar sequence identity to the polypeptides having amino acid residues 20-519 of SEQ ID NO:6 and/or amino acid residues 33-532 of SEQ ID NO:8, or their orthologs. The term “substantially similar sequence identity” is used herein to denote polypeptides comprising at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99-0.5%, or greater than 99.5% sequence identity to the sequences shown in amino acid residues 20-519 of SEQ ID NO:6 and/or amino acid residues 33-532 of SEQ ID NO:8, or their orthologs. The present invention further includes nucleic acid molecules that encode such polypeptides. Methods for determining percent identity are described PCT publications WO 02/00721 (incorporated by reference) and 04/003140 (incorporated by reference).
- The present invention provides a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of an anti-IL-31RA antibody or fragment to the patient, wherein the anti-IL-31RA antibody or fragment binds with an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or great than 99.5% sequence identity with amino acid residues 20-519 of SEQ ID NO:6 or portion thereof, or amino acid residues 33-532 of SEQ ID NO:8 or portion thereof, and wherein the anti-IL-31RA antibody or fragment prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus. The anti-IL-31RA antibody may optionally be a polyclonal antibody or a neutralizing monoclonal antibody (the present invention also provides for a hybridoma for producing the neutralizing IL-31RA monoclonal antibody). The anti-IL-31RA antibody fragment may optionally be a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, single chain Fv (scFV), dual specific antibody, domain antibody, or bispecific antibody. The anti-IL-31RA antibody or fragment may bind with amino acid residues 20-277 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8. The anti-IL-31RA antibody or fragment may bind with about 4-10 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8. The anti-IL-31RA antibody or fragment may bind with about 10-14 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8. The anti-IL-31RA antibody or fragment may bind with about 14-30 amino acid residues of amino acid residues 20-519 of SEQ ID NO:6 or amino acid residues 33-532 of SEQ ID NO:8. The anti-IL-31 antibody or fragment may be further conjugated to a polyethylene glycol or to human serum albumin.
- The present invention also provides for a method of treating a patient suffering from a skin disorder, the method comprises administering a therapeutically effective amount of a soluble IL-31RA receptor to the patient, wherein the soluble IL-31RA receptor has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or great than 99.5% sequence identity with amino acid residues 20-519 of SEQ ID NO:6 or portion thereof, or amino acid residues 33-532 of SEQ ID NO:8, and wherein the soluble IL-31RA receptor binds with an IL-31 polypeptide consisting of amino acid residues 1-164 SEQ ID NO:2, and wherein the soluble IL-31RA receptor prevents, inhibits the progression of, delays the onset of, reduces the severity of, and/or inhibits at least one of the conditions or symptoms of the skin disorder selected from the group consisting of Atopic Dermititis, Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus. The soluble IL-31RA receptor may comprise amino acid residues 20-519 of SEQ ID NO:6 or 33-240 of SEQ ID NO:8, amino acid residues 1-324 of SEQ ID NO:10, or amino acid residues 1-239 of SEQ ID NO:12. The soluble IL-31RA receptor may be further conjugated to the Fc region of the various immunoglobulins (IgG, IgA, IgD, IgM or IgE). Optionally, the soluble IL-31RA receptor may be an IL-31RA homodimer or an IL-31RA/OSMRbeta heterodimer. The soluble IL-31RA receptor may bind with an IL-31 polypeptide comprising, consisting essentially of, consisting of amino acid residues 24-164 of SEQ ID NO:2 or 27-164 of SEQ ID NO:2. The soluble IL-31RA receptor may be further conjugated to a polyethylene glycol or to human serum albumin.
- A variety of assays known to those skilled in the art can be utilized to detect antibodies which bind to IL-31RA proteins or polypeptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant IL-31RA protein or polypeptide.
- Antibodies to IL-31RA may be used for tagging cells that express IL-31RA; for isolating IL-31RA by affinity purification; for diagnostic assays for determining circulating levels of IL-31RA polypeptides; for detecting or quantitating soluble IL-31RA as a marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block IL-31 activity in vitro and in vivo. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications. In addition, antibodies to IL-31RA or fragments thereof may be used in vitro to detect denatured IL-31RA or fragments thereof in assays, for example, Western Blots or other assays known in the art.
- Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria, toxin, saporin, Pseudomonas exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/anticomplementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/anticomplementary pair.
- Polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the polypeptide has multiple functional domains (i.e., an activation domain or a receptor binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting carrier or vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/cytotoxic molecule conjugates.
- Both skin-homing T cells and epidermal keratinocytes have been implicated in the pathology of skin diseases in humans. As shown in Example 1 herein, of the T cell subsets, IL-31 mRNA and protein expression is restricted to the skin-homing CLA+ T cell population in humans. As such, an antagonist to IL-31RA, including an antibody or fragment thereof or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors) antagonist will be useful in treating, ablating, inhibiting the progression of, and/or reducing the severity of skin and epidermal diseases which have expression of CLA+ T cells. Such diseases include, for example, atopic dermatitis, contact dermatitis, psoriasis, drug-induced allergic reactions, skin-tropic viruses and viral associated pruritis, vitiligo, cutaneous T cell lymphoma, alopecia aerata, acne rosacea, acne vulgaris, prurigo nodularis, and bullous pemphigoid.
- Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease with a dramatically increasing incidence over the last decades. Clinically AD is characterized by highly pruritic often excoriated plaques and papules that show a chronic relapsing course. The diagnosis of AD is mostly based on major and minor clinical findings. See Hanifin J M, Arch Dermatol: 135, 1551 (1999). Histopathology reveals spongiosis, hyper and focal parakeratosis in acute lesions, whereas marked epidermal hyperplasia with hyper and parakeratosis, acanthosis/hypergranulosis and perivascular infiltration of the dermis with lymphocytes and abundant mast cells are the hallmarks of chronic lesions.
- T cells play a central role in the initiation of local immune responses in tissues and evidence suggests that skin-infiltrating T cells in particular, may play a key role in the initiation and maintenance of disregulated immune responses in the skin. Approximately 90% of infiltrating T cells in cutaneous inflammatory sites express the cutaneous lymphocyte-associated Ag (CLA+) which binds E-selectin, an inducible adhesion molecule on endothelium (reviewed in Santamaria-Babi L. F., et al., Eur J Dermatol: 14, 13, (2004)). A significant increase in circulating CLA+ T cells among AD patients compared with control individuals has been documented (See Teraki Y., et al., Br J Dermatol: 143, 373 (2000)), while others have demonstrated that memory CLA+ T cells from AD patients preferentially respond to allergen extract compared to the CLA− population (See Santamaria-Babi, L. F., et al., J Exp Med: 181, 1935, (1995)). In humans, the pathogenesis of atopic disorders of the skin have been associated with increases in CLA+ T cells that express increased levels of Th-2-type cytokines like IL-5 and IL-13. See Akdis M., et al., Eur J Immunol: 30, 3533 (2000); and Hamid Q., et al., J Allergy Clin Immunol: 98, 225 (1996).
- NC/Nga Mice spontaneously develop AD-like lesions that parallel human AD in many aspects, including clinical course and signs, histopathology and immunopathology when housed in non-specified pathogen-free (non-SPF) conditions at around 6-8 weeks of age. In contrast, NC/Nga mice kept under SPF conditions do not develop skin lesions. However, onset of spontaneous skin lesions and scratching behaviour can be synchronized in NC/Nga mice housed in a SPF facility by weekly intradermal injection of crude dust mite antigen. See Matsuoka H., et al., Allergy: 58, 139 (2003). Therefore, the development of AD in NC/Nga is a useful model for the evaluation of novel therapeutics for the treatment of AD.
- In addition to the NC/Nga model of spontaneous AD, epicutaneous sensitization of mice using OVA can also be used as a model to induce antigen-dependent epidermal and dermal thickening with a mononuclear infiltrate in skin of sensitized mice. This usually coincides with elevated serum levels of total and specific IgE, however no skin barrier dysfunction or pruritus normally occurs in this model. See Spergel J. M., et al., J Clin Invest, 101: 1614, (1998). This protocol can be modified in order to induce skin barrier disregulation and pruritis by sensitizing DO11.10 OVA TCR transgenic mice with OVA. Increasing the number of antigen-specific T cells that could recognize the sensitizing antigen may increase the level of inflammation in the skin to induce visible scratching behaviour and lichenification/scaling of the skin.
- Both the NC/Nga spontaneous AD model and the OVA epicutaneous DO11.10 model are used to investigate expression of IL-31 and IL-31RA in AD. See Example 3.
- An IL-31RA neutralizing antagonist could be effective in inhibiting, reducing, minimizing or preventing atopic dermatitis reactions. See Example 3 for an in vivo model for testing the effect of an IL-31 antagonist in an atopic dermatitis model.
- Allergic contact dermatitis is defined as a T cell mediated immune reaction to an antigen that comes into contact with the skin. The CLA+ T cell population is considered to be involved in the initiation of dermatitis since allergen dependent T cell responses are largely confined to the CLA+ population of cells (See Santamaria-Babi, L. F., et al., J Exp Med: 181, 1935, (1995)). Recent data has found that only memory (CD45RO+) CD4+ CLA+ and not CD8+ T cells proliferate and produce both type-1 (IFN-γ) and type-2 (IL-5) cytokines in response to nickel, a common contact hypersensitivity allergen. Furthermore, cells expressing CLA in combination with CD4, CD45RO (memory) or CD69 are increased after nickel-specific stimulation and express the chemokine receptors CXCR3, CCR4, CCR10 but not CCR6. See Moed H., et al., Br J Dermatol: 51, 32, (2004).
- In animal models, it has been demonstrated that allergic contact dermatitis is T-cell dependent and that the allergic-responsive T cells migrate to the site of allergen application. See generally: Engeman T. M., et al., J Immunol: 164, 5207, (2000); Ferguson T. A. & Kupper T. S. J Immunol: 150, 1172, (1993); and Gorbachev A. V. & Fairchild R. L. Crit Rev Immunol: 21, 451(2001). Since CLA+ T cells produce IL-31 and IL-31 stimulation of skin keratinocytes can induce pro-inflammatory chemokines, IL-31 may be involved in the pathophysiology of contact dermatitis.
- An IL-31RA neutralizing antagonist, e.g., antibody or fragment thereof or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors), could be effective in inhibiting, reducing, minimizing or preventing contact dermatitis reactions. See Example 2 for an in vivo model for testing the effect of an IL-31 antagonist in a contact dermatitis model.
- Drug-induced delayed type cutaneous allergic reactions are very heterogeneous and may mirror many distinct pathophysiological events. See Brockow K., et al., Allergy, 57, 45 (2002). Immunological mechanisms involved in these reactions have been shown as either antibody or cell mediated. In immediate drug allergy an IgE-mediated antibody reaction can be demonstrated by a positive skin prick and/or intradermal test after 20 min, whereas non-immediate reactions to drugs can occur more than one hour after last drug intake and are often T-cell mediated. Non-immediate T-cell mediated delayed type reactions can occur in patients with adverse drug reactions to penicillins for example Proliferative T cell responses to penicillins have been shown to be restricted to the memory (CD45RO+) CLA+ subpopulation of T cells from penicillin allergic patients whereas the CD45RO+ CLA− subset shows no proliferative response. See Blanca M., Leyva L., et al., Blood Cells Mol Dis: 31, 75 (2003). Delayed-type hypersensitivity (DTH) reactions can be artificially reproduced in mice, allowing assessment of factors that may be involved in the initiation and perpetuation of the DTH response. An IL-31RA neutralizing antagonist, e.g., antibody or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors), could be effective in inhibiting, reducing, minimizing or preventing delayed type hypersensitivity reactions. See Example 4 for an in vivo model of testing the effect of an IL-31 antagonist in a DTH model.
- Toxic epidermal necrolysis (TEN) is a very rare but extremely severe drug reaction characterized by widespread apoptosis of epidermis with extensive blisters. Studies have shown that lymphocytes infiltrating the blister are CLA+ T cells and can exhibit cytotoxicity towards epidermal keratinocytes. See Leyva L., et al., J Allergy Clin Immunol: 105, 157 (2000); and Nassif A., Bensussan A., et al., J Allergy Clin Immunol: 114, 1209 2004). A transgenic mouse system, whereby OVA is expressed under the control of the keratin-5 (K5) promoter in the epidermal and hair follicular keratinocytes of mice, has been generated to establish an animal model for TEN. OVA specific CD8+ T cells, when adoptively transferred into K5-OVA mice, undergo activation and proliferation in the skin-draining lymph nodes and target the skin of K5-OVA mice, resulting in development of skin lesions that are reminiscent of TEN. See Azukizawa H., et al., Eur J Immunol: 33, 1879 (2003). An IL-31RA neutralizing antagonist, e.g., antibody or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors), could be effective in inhibiting, reducing, minimizing or preventing TEN reactions.
- Bullous pemphigoid is a subepidermal disorder which manifests as subepidermal blisters with a dermal infiltrate of neutrophils and eosinophils. Diagnosis is characterized by the presence of antigen-specific antibodies against specific adhesion proteins of the epidermis and dermal-epidermal junction. See Jordon R. E., et al., JAMA: 200, 751 (1967). Studies analyzing the role of T cells in the pathogenesis of bullous pemphigoid by analysis of PBL and skin blister T cells have found a predominance of CLA+ T cells expressing increased levels of Th2-cytokines like IL-4 and IL-13. See Teraki Y., et al., J Invest Dermatol: 117, 1097 (2001). In bullous pemphigoid patients following therapy with systemic corticosteroids, the frequency of CLA+, but not CLA−, interleukin-13-producing cells is significantly decreased. Decreases in CLA+ cells following corticosteroid treatment is associated with clinical improvement. See Teraki, ibid. Neutralization of IL-31 by an IL-31RA antagonist, e.g., antibody or fragment thereof or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors), may improve clinical outcome of bullous pemohigoid.
- Alopecia areata (AA) is regarded as a tissue-restricted autoimmune disease of hair follicles in which follicular activity is arrested because of the continued activity of lymphocytic infiltrates. AA results in patches of complete hair loss anywhere on the body, though actual loss of hair follicles does not occur, even in hairless lesions. Although clinical signs of inflammation are absent, skin biopsies from sites of active disease show perifollicular lymphocytic inflammation of primarily CD4+ cells, along with a CD8+ intrafollicular infiltrate. See Kalish R. S. & Gilhar A. J Investig Dermatol Symp Proc: 8, 164 (2003).
- Studies have shown that scalp skin infiltrating CD4+ or CD8+ lymphocytes express CLA and, in peripheral blood of individuals with AA, the percent of CLA+CD4+ or CD8+ lymphocytes is significantly higher than that of normal controls. Furthermore, patients with severe or progressive AA show a much higher CLA-positivity compared to patients recovering from the disease and a decrease in percent CLA+ cells parallels a good clinical course. See Yano S., et al., Acta Derm Venereol: 82, 82 (2002). These studies therefore suggest that CLA+ lymphocytes may play an important role in AA. Xenograft models have demonstrated that activated T cells are likely to play a role in the pathogenesis of AA. Lesional scalp from AA patients grafted onto nude mice regrows hair coincident with a loss of infiltrating lymphocytes from the graft and, transfer of activated lesional T cells to SCID mice can transfer hair loss to human scalp explants on SCID mice. See Kalish R. S. & Gilhar A. J Investig Dermatol Symp Proc: 8, 164 (2003).
- A variety of immunomodulating therapies are part of the usual treatment for this disorder however none of these treatments have been consistent in their efficacy. See Tang L., et al., J Invest Dermatol: 120, 400 (2003); Tang L., et al., (2004); and Tang L., et al., J Am Acad Dermatol: 49, 1013 (2003). Neutralizing anti-IL-31RA antibody or fragment thereof or IL-31RA soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors) may be effective to limit, reduce, inhibit, or prevent the effects of the development of AA.
- Acne vulgaris, a disorder of the pilosebaceous apparatus, is the most common skin problem of adolescence. Abnormalities in follicular keratinization are thought to produce the acne lesion. Acne rosacea is differentiated from acne vulagaris by the presence of red papules, pustules, cysts and extensive telangiectasias, but the absence of comedones (white heads). Increased sebum excretion from sebaceous glands is a major factor in the pathophysiology of acne vulgaris. Other sebaceous gland functions are also associated with the development of acne, including sebaceous proinflammatory lipids; different cytokines produced locally; periglandular peptides and neuropeptides, such as corticotrophin-releasing hormone, which is produced by sebocytes; and substance P, which is expressed in the nerve endings at the vicinity of healthy-looking glands of acne patients. See Zouboulis C. C. Clin Dermatol: 22, 360 (2004).
- Although the pathophysiology of acne vulgaris and acne rosacea remains unknown, clinical observations and histopathologic studies suggest that inflammation of the pilosebaceous follicle may be central to the pathogenesis of rosacea and acne vulgaris. Early studies on analysis of T cell subsets infiltrating rosacea legions indicated that the majority of T cells expressed CD4. See Rufli T. & Buchner S. A. Dermatologica: 169, 1 (1984).
- CD4+ T cells produce IL-31 and IHC analysis of skin for IL-31 expression suggests that IL-31 is expressed in sebaceous and sweat glands. IL-31 stimulation of epidermal keratinocytes induces expression of chemokines which likely results in cellular infiltration suggesting that IL-31 may contribute to the pro-inflammatory response in skin. IL-31 may therefore contribute to the pathophysiology of acne rosacea and acne vulgaris. Accordingly, an IL-31RA antagonist, such as an anti-IL-31RA antibody or fragment thereof, or an IL-31RA soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors) can be useful to treat, reduce the severity of, inhibit the progression of, ablate, and/or eliminate one or more symptoms associated with acne rosacea and acne vulgaris.
- Prurigo nodularis is an eruption of lichenified or excoriated nodules caused by intractable pruritus that is difficult to treat. While chronic rubbing results in lichenification, and scratching in linear excoriations, individuals who pick and gouge at their itchy, irritated skin tend to produce markedly thickened papules known as prurigo nodules. Although prurigo nodularis is not specific to atopic dermatitis, many patients with these nodules also have an atopic reaction, which manifests as allergic rhinitis, asthma, or food allergy. T cells represent the majority of infiltrating cells in prurigo lesions and these lesions often represents the most pruritic skin lesion in atopy patients.
- Topical treatment of prurigo nodularis with capsaicin, an anti-pruritic alkaloid that interferes with the perception of pruritis and pain by depletion of neuropeptides like substance P in small sensory cutaneous nerves, has proven to be an effective and safe regimen resulting in clearing of the skin lesions. See Stander S., et al., J Am Acad Dermatol: 44, 471 (2001). Studies of the itch response in NC/Nga mice using capsaicin treatment showed that the spontaneous development of dermatitis lesions was almost completely prevented. Furthermore, the elevation of serum IgE levels was significantly suppressed and infiltrating eosinophils and mast cell numbers in lesional skin of capsaicin treated mice were reduced. See Mihara K., et al., Br J Dermatol: 151, 335 (2004). The observations from this group suggest that scratching behaviour might contribute to the development of dermatitis by enhancing various immunological responses, therefore implying that prevention of the itch sensation and/or itch-associated scratching behaviour might be an effective treatment for AD. See Mihara K., et al., Br J Dermatol: 151, 335 (2004).
- Chronic delivery of IL-31 induces pruritis and alopecia in mice followed by the development of skin lesions resembling dermatitis suggesting that IL-31 induces itching. See Dillon S. R., et al., Nat Immunol: 5, 752 (2004). The involvement of IL-31 was tested in induction of the itch response by two methods (i) capsaicin treatment of IL-31-treated mice and (ii) IL-31 treatment of Tac1 knockout mice, which have significantly reduced nociceptive pain responses because of lack of expression of neuropeptides in Example 5. In addition, whether neutralization of IL-31 in IL-31 treated mice could prevent pruritis and alopecia was tested in Example 5.
- Herpes Simplex Virus (HSV)-specific CD8+ T cells in the peripheral blood and HSV-specific CD8+ T cells recovered from herpes lesions express high levels of CLA where as non-skin-tropic herpes virus-specific CD8+ T cells lack CLA expression. See Koelle D. M., et al., J Clin Invest: 110, 537 (2002). HSV-2 reactive CD4+ T lymphocytes also express CLA, but at levels lower than those previously observed for CD8+ T lymphocytes. See Gonzalez J. C., et al., J Infect Dis: 191, 243 (2005). Pruritis has also been associated with herpes viral infections (See Hung K. Y., et al., Blood Purif: 16, 147 (1998), though other viral diseases, like HIV, have also been associated with pruritic skin lesions. Severe, intractable pruritus, often associated with erythematopapular skin lesions and hypereosinophilia, is a condition observed in some nonatopic, HIV-infected patients 36. See Singh F. & Rudikoff D, Am J Clin Dermatol; 4, 177 (2003); and Milazzo F., Piconi S., et al., Allergy: 54, 266 (1999).
- The association of skin-tropic viruses with pruritis and CLA+ T cells suggests that IL-31 producing T cells may be involved in the pathophysiology of viral infections.
- Inflammation is a protective response by an organism to fend off an invading agent. Inflammation is a cascading event that involves many cellular and humoral mediators. On one hand, suppression of inflammatory responses can leave a host immunocompromised; however, if left unchecked, inflammation can lead to serious complications including chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and the like), septic shock and multiple organ failure. Importantly, these diverse disease states share common inflammatory mediators. The collective diseases that are characterized by inflammation have a large impact on human morbidity and mortality. Therefore it is clear that anti-inflammatory molecules, such as anti-IL-31RA antibodies and fragments thereof, and IL-31RA soluble receptors as described herein, could have crucial therapeutic potential for a vast number of human and animal diseases, from asthma and allergy to autoimmunity and septic shock. As such, use of anti-inflammatory anti-IL-31RA antibodies and fragments thereof, and IL-31RA soluble receptors as described herein can be used therapeutically as IL-31RA antagonists for treating, reducing the severity of, inhibiting the progression of, and ablating diseases such as arthritis, endotoxemia, inflammatory bowel disease, psoriasis, related disease and the like.
- IL-31 has been shown to induce several chemokine and cytokine genes in normal human epidermal keratinocytes (NHEKs), including genes encoding GROα, (CXCL1), TARC (CCl17), MIP3β, (CCL19), MDC (CCL22), MIP-3 (CCL23), MIP-1β (CCL4), and I-309. See Dillon S. R., et al., Nat Immunol: 5, 752 (2004). TARC and MDC bind CCR4, a chemokine receptor associated with Th2-type T cells and predominantly expressed by CLA+ T cells in peripheral blood. Both chemokines have been implicated in the recruitment of T cells into the skin of AD patients suggesting that these chemokines contribute to the inflammatory process associated with the pathogenesis of AD. See Example 10 for a model to measure the reduction in TARC and MDC levels by administering an IL-31 antagonist.
- Psoriasis is a chronic skin condition that affects more than seven million Americans. Psoriasis occurs when new skin cells grow abnormally, resulting in inflamed, swollen, and scaly patches of skin where the old skin has not shed quickly enough. Plaque psoriasis, the most common form, is characterized by inflamed patches of skin (“lesions”) topped with silvery white scales. Psoriasis may be limited to a few plaques or involve moderate to extensive areas of skin, appearing most commonly on the scalp, knees, elbows and trunk. Although it is highly visible, psoriasis is not a contagious disease. The pathogenesis of the diseases involves chronic inflammation of the affected tissues. Anti-IL-31RA antibodies and fragment thereof and soluble receptors (IL-31RA and IL-31RA/OSMRbeta soluble receptors) could serve as a valuable therapeutic to treat, inhibit the progression of, reduce the severity of, reduce inflammation and pathological effects in psoriasis, other inflammatory skin diseases, skin and mucosal allergies, and related diseases.
- Psoriasis is a T-cell mediated inflammatory disorder of the skin that can cause considerable discomfort. It is a disease for which there is no cure and affects people of all ages. Psoriasis affects approximately two percent of the populations of European and North America. Although individuals with mild psoriasis can often control their disease with topical agents, more than one million patients worldwide require ultraviolet or systemic immunosuppressive therapy. Unfortunately, the inconvenience and risks of ultraviolet radiation and the toxicities of many therapies limit their long-term use. Moreover, patients usually have recurrence of psoriasis, and in some cases rebound, shortly after stopping immunosuppressive therapy.
- The present invention provides a method for inhibiting activation or differentiation of monocytes/macrophages. Monocytes are incompletely differentiated cells that migrate to various tissues where they mature and become macrophages. Macrophages play a central role in the immune response by presenting antigen to lymphocytes and play a supportive role as accessory cells to lymphocytes by secreting numerous cytokines. Macrophages can internalize extracellular molecules and upon activation have an increased ability to kill intracellular microorganisms and tumor cells. Activated macrophages are also involved in stimulating acute or local inflammation.
- The molecules of the present invention have particular use in the monocyte/macrophage arm of the immune system. Methods are known that can assess such activity. For example, interferon gamma (IFN-γ) is a potent activator of mononuclear phagocytes. For example, an increase in expression of IL-31RA upon activation of THP-1 cells (ATCC No. TIB-202) with interferon gamma could suggest that this receptor is involved in monocyte activation. Monocytes are incompletely differentiated cells that migrate to various tissues where they mature and become macrophages. Macrophages play a central role in the immune response by presenting antigen to lymphocytes and play a supportive role as accessory cells to lymphocytes by secreting numerous cytokines. Macrophages can internalize extracellular molecules and upon activation have an increased ability to kill intracellular microorganisms and tumor cells. Activated macrophages are also involved in stimulating acute or local inflammation. Moreover, monocyte-macrophage function has been shown to be abnormal in a variety of diseased states. For example see, Johnston, R B, New Eng. J. Med. 318:747-752, 1998.
- One of skill in the art would recognize that agonists of IL-31RA receptor, such as agonist IL-31RA antibody, are useful. For example, depressed migration of monocytes has been reported in populations with a predisposition to infection, such as newborn infants, patients receiving corticosteroid or other immunosuppressive therapy, and patients with diabetes mellitus, burns, or AIDS. Agonists for IL-31RA, such as agonist IL-31RA antibody, could result in an increase in the ability of monocytes to migrate and possibly prevent infection in these populations. There is also a profound defect of phagocytic killing by mononuclear phagocytes from patients with chronic granulomatous disease. This results in the formation of subcutaneous abscesses, as well as abscesses in the liver, lungs, spleen, and lymph nodes. An agonist of IL-31RA receptor such as agonist IL-31RA antibody, could correct or improve this phagocytic defect. In addition, defective monocyte cytotoxicity has been reported in patients with cancer and Wiskott-Aldrich syndrome (eczema, thrombocytopenia, and recurrent infections). Activation of monocytes by agonists of IL-31RA receptor, such as agonist IL-31RA antibody, could aid in treatment of these conditions. The monocyte-macrophage system is prominently involved in several lipid-storage diseases (sphingolipidoses) such as Gaucher's disease. Resistance to infection can be impaired because of a defect in macrophage function, which could be treated by agonists to IL-31RA receptor such as agonist IL-31RA antibody.
- Using methods known in the art, and disclosed herein, one of skill could readily assess the activity of IL-31RA agonists and antagonists in diseases that have a high correlation of CLA+ T cells. In addition, as IL-31 is expressed in a T-cell, macrophage and monocyte-specific manner, and these diseases involve abnormalities in monocytic cells, such as cell proliferation, function, localization, and activation, the polynucleotides, polypeptides, and antibodies of the present invention can be used to as diagnostics to detect such monocytic cell abnormalities, and indicate the presence of disease. Such methods involve taking a biological sample from a patient, such as blood, saliva, or biopsy, and comparing it to a normal control sample. Histological, cytological, flow cytometric, biochemical and other methods can be used to determine the relative levels or localization of IL-31, or cells expressing IL-31, i.e., monocytes, in the patient sample compared to the normal control. A change in the level (increase or decrease) of IL-31 expression, or a change in number or localization of monocytes (e.g., increase or infiltration of monocytic cells in tissues where they are not normally present) compared to a control would be indicative of disease. Such diagnostic methods can also include measuring TARC and MDC, for example. Such methods are well known in the art and disclosed herein. IL-31RA antagonists, such as anti-IL-31RA antibodies, can be used to modulate the immune system by binding IL-31RA receptor, and thus, preventing the binding of IL-31 with endogenous IL-31 receptor. Alternatively, IL-31RA antagonists, such as soluble IL-31RA and IL-31RA/OSMRbeta receptors, can also be used to modulate the immune system by inhibiting the binding of IL-31 with the endogenous IL-31RA receptor. Accordingly, the present invention includes the use of IL-31RA antibodies and fragments thereof as well as IL-31RA soluble receptors (IL-31RAa do IL-31RA/OSMRbeta) which can be administered to a subject which has excess IL-31. IL-31RA antagonists (e.g., anti-IL-31RA antibodies and fragments thereof and soluble IL-31RA and soluble IL-31RA/OSMRbeta receptors) can be also used to treat diseases that have a high correlation of CLA+ T cells. Suitable subjects include mammals, such as humans
- IL-31 has been shown to be expressed in activated mononuclear cells, and may be involved in regulating inflammation. As such, antibodies and soluble receptors of the present invention can be assayed and used for their ability to modify inflammation, or can be used as a marker for inflammation. Methods to determine proinflammatory and anti-inflammatory qualities of IL-31 are known in the art and discussed herein. Moreover, it may be involved in up-regulating the production of acute phase reactants, such as serum amyloid A (SAA), α1-antichymotrypsin, and haptoglobin, and that expression of IL-31RA receptor may be increased upon injection of lipopolysaccharide (LPS) in vivo that are involved in inflammatory response (Dumoutier, L. et al., Proc. Nat'l. Acad. Sci. 97:10144-10149, 2000). Production of acute phase proteins, such as SAA, is considered a short-term survival mechanism where inflammation is beneficial; however, maintenance of acute phase proteins for longer periods contributes to chronic inflammation and can be harmful to human health. For review, see Uhlar, C M and Whitehead, A S, Eur. J. Biochem. 265:501-523, 1999, and Baumann H. and Gauldie, J. Immunology Today 15:74-80, 1994. Moreover, the acute phase protein SAA is implicated in the pathogenesis of several chronic inflammatory diseases, is implicated in atherosclerosis and rheumatoid arthritis, and is the precursor to the amyloid A protein deposited in amyloidosis (Uhlar, C M and Whitehead, supra.). Thus, where a ligand such as IL-31 that acts as a pro-inflammatory molecule and induces production of SAA, antagonists would be useful in treating inflammatory disease and other diseases associated with acute phase response proteins induced by the ligand. Such antagonists are provided by the present invention. For example, a method of reducing inflammation comprises administering to a mammal with inflammation a therapeutically effective amount of a composition comprising anti-IL-31RA antibody (e.g., neutralizing antibody) or fragment thereof, or a soluble receptor (e.g., IL-31RA and IL-31RA/OSMRbeta soluble receptors) that is sufficient to reduce inflammation. Moreover, a method of suppressing an inflammatory response in a mammal with inflammation can comprise: (1) determining a level of serum amyloid A protein; (2) administering a composition comprising an anti-IL-31RA antibody as described herein or soluble receptor (IL-31RA and IL-31RA/OSMRbeta soluble receptors) in an acceptable pharmaceutical carrier; (3) determining a post administration level of serum amyloid A protein; (4) comparing the level of serum amyloid A protein in step (1) to the level of serum amyloid A protein in step (3), wherein a lack of increase or a decrease in serum amyloid A protein level is indicative of suppressing an inflammatory response.
- Moreover, anti-IL-31RA antibodies and fragments thereof that block the binding and/or signaling of IL-31 to IL-31RA, and soluble IL-31RA receptors (IL-31RA and IL-31RA/OSMRbeta) that bind IL-31 and thus prevent the binding of IL-31 to cellular-based IL-31RA are useful to antagonize or block signaling of IL-31 and are thus useful in the treatment of, inhibit the progression of, reduce the severity of, reduce one or more symptoms associated with Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, and Herpes simplex virus.
- Anti-IL-31RA antibodies, and soluble IL-31RA (IL-31RA and IL-31RA/OSMRbeta soluble receptors) comprising receptors are useful as antagonists of IL-31. Such antagonistic effects can be achieved by direct neutralization or binding of its natural ligand. In addition to antagonistic uses, the soluble receptors can bind IL-31 and act as carrier or carrier proteins, in order to transport IL-31 to different tissues, organs, and cells within the body. As such, the soluble receptors can be fused or coupled to molecules, polypeptides or chemical moieties that direct the soluble-receptor-Ligand complex to a specific site, such as a tissue, specific immune cell, monocytes, or tumor. For example, in acute infection or some cancers, benefit may result from induction of inflammation and local acute phase response proteins. Thus, the soluble receptors described herein or antibodies (and fragments thereof) of the present invention can be used to specifically direct the action of a pro-inflammatory IL-31 ligand. See, Cosman, D. Cytokine 5: 95-106, 1993; and Fernandez-Botran, R. Exp. Opin. Invest. Drugs 9:497-513, 2000.
- IL-31 may also be used within diagnostic systems for the detection of circulating levels of ligand, and in the detection of acute phase inflammatory response. Within a related embodiment, antibodies or other agents that specifically bind to IL-31, e.g., soluble IL-31RA and soluble IL-31RA/OSMRbeta, can be used to detect circulating IL-31 polypeptides. Elevated or depressed levels of ligand or receptor polypeptides may be indicative of pathological conditions, including inflammation or cancer. Moreover, detection of acute phase proteins or molecules such as IL-31 can be indicative of a chronic inflammatory condition in certain disease states (e.g., rheumatoid arthritis). Detection of such conditions serves to aid in disease diagnosis as well as help a physician in choosing proper therapy.
- Generally, the dosage of administered IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. Typically, it is desirable to provide the recipient with a dosage of IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor which is in the range of from about 1 pg/kg to 10 mg/kg (amount of agent/body weight of patient), although a lower or higher dosage also may be administered as circumstances dictate. One skilled in the art can readily determine such dosages, and adjustments thereto, using methods known in the art.
- Administration of IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor to a subject can be topical, intradermal, inhalant, intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, by perfusion through a regional catheter, or by direct intralesional injection. When administering therapeutic proteins by injection, the administration may be by continuous infusion or by single or multiple boluses.
- Additional routes of administration include oral, mucosal-membrane, pulmonary, and transcutaneous. Oral delivery is suitable for polyester microspheres, zein microspheres, proteinoid microspheres, polycyanoacrylate microspheres, and lipid-based systems (see, for example, DiBase and Morrel, “Oral Delivery of Microencapsulated Proteins,” in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 255-288 (Plenum Press 1997)). The feasibility of an intranasal delivery is exemplified by such a mode of insulin administration (see, for example, Hinchcliffe and Illum, Adv. Drug Deliv. Rev. 35:199 (1999)). Dry or liquid particles comprising IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor can be prepared and inhaled with the aid of dry-powder dispersers, liquid aerosol generators, or nebulizers (e.g., Pettit and Gombotz, TIBTECH 16:343 (1998); Patton et al., Adv. Drug Deliv. Rev. 35:235 (1999)). This approach is illustrated by the AERX diabetes management system, which is a hand-held electronic inhaler that delivers aerosolized insulin into the lungs. Studies have shown that proteins as large as 48,000 kDa have been delivered across skin at therapeutic concentrations with the aid of low-frequency ultrasound, which illustrates the feasibility of trascutaneous administration (Mitragotri et al., Science 269:850 (1995)). Transdermal delivery using electroporation provides another means to administer IL-31RA antibody or fragment thereof or soluble IL-31RA receptor or soluble IL-31RA/OSMRbeta receptor (Potts et al., Pharm. Biotechnol. 10:213 (1997)).
- A pharmaceutical composition comprising a IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a “pharmaceutically acceptable carrier” if its administration can be tolerated by a recipient patient. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers are well-known to those in the art. See, for example, Gennaro (ed.), Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company 1995).
- For purposes of therapy, an IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor and a pharmaceutically acceptable carrier are administered to a patient in a therapeutically effective amount. A combination of an IL-31RA antibody (antagonist and agonist) or a soluble IL-31RA receptor (e.g., IL-31RA homodimer and a zcytor17/OSMRbeta heterodimer) and a pharmaceutically acceptable carrier is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient. For example, an agent used to treat inflammation is physiologically significant if its presence alleviates at least a portion of the inflammatory response.
- A pharmaceutical composition comprising an IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor can be furnished in liquid form, in an aerosol, or in solid form. Liquid forms, are illustrated by injectable solutions, aerosols, droplets, topological solutions and oral suspensions. Exemplary solid forms include capsules, tablets, and controlled-release forms. The latter form is illustrated by miniosmotic pumps and implants (Bremer et al., Pharm. Biotechnol. 10:239 (1997); Ranade, “Implants in Drug Delivery,” in Drug Delivery Systems, Ranade and Hollinger (eds.), pages 95-123 (CRC Press 1995); Bremer et al., “Protein Delivery with Infusion Pumps,” in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 239-254 (Plenum Press 1997); Yewey et al., “Delivery of Proteins from a Controlled Release Injectable Implant,” in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 93-117 (Plenum Press 1997)). Other solid forms include creams, pastes, other topological applications, and the like.
- An IL-31RA antibody or fragment thereof (antagonist and agonist) or a soluble IL-31RA receptor or a soluble IL-31RA/OSMRbeta receptor can be encapsulated within liposomes using standard techniques of protein microencapsulation (see, for example, Anderson et al., Infect. Immun. 31:1099 (1981), Anderson et al., Cancer Res. 50:1853 (1990), and Cohen et al., Biochim. Biophys. Acta 1063:95 (1991), Alving et al. “Preparation and Use of Liposomes in Immunological Studies,” in Liposome Technology, 2nd Edition, Vol. III, Gregoriadis (ed.), page 317 (CRC Press 1993), Wassef et al., Meth. Enzymol. 149:124 (1987)). As noted above, therapeutically useful liposomes may contain a variety of components. For example, liposomes may comprise lipid derivatives of poly(ethylene glycol) (Allen et al., Biochim. Biophys. Acta 1150:9 (1993)).
- Other dosage forms can be devised by those skilled in the art, as shown, for example, by Ansel and Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Edition (Lea & Febiger 1990), Gennaro (ed.), Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company 1995), and by Ranade and Hollinger, Drug Delivery Systems (CRC Press 1996).
- The complete disclosure of all patents, patent applications, and publications, and electronically available material (e.g., GenBank amino acid and nucleotide sequence submissions) cited herein are incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.
- Selection of Study Subjects and Biopsies
- Twelve patients with AD (moderate to severe disease; median age was 32 years old with skin involvement of 5-45%), 6 patients with psoriasis (median age was 56 years old with skin involvement of 10-65%) and 12 healthy individuals (median age 34 years) were included in A study after informed consent. None of the patients had received any systemic corticosteroids previously. All patients were off topical corticosteroids for one week before their skin biopsy or blood drawing. Two mm punch biopsies were taken from 1) acute erythematous AD lesions of less than three days' onset, 2) chronic, lichenified AD lesions of greater than two weeks' duration, 3) chronic psoriasis lesions, and 4) normal skin. The skin samples were immediately frozen at −70° C. for immunohistochemistry or Western and immuno-dot blotting.
- Isolation and Activation of Primary Human T Cell Subsets:
- To isolate various T cell subsets, human PBMCs from the donors were isolated using standard Ficoll gradient centrifugation. Total T cells were then isolated using the T Cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer's instructions. Separation efficiency was assessed using standard flow cytometry and determined to be >95% T cells. To separate CD45RA+“naïve” T cells from the CD45RO+“memory” T cells, the total T cell population was incubated with anti-CD45RO microbeads (Miltenyi Biotec) for 15 minutes at +4° C. and magnetically separated according to the manufacturers instructions. The naïve and memory T cell populations were determined to be >90% pure by flow cytometry.
- CD45RO+ memory T cells are often tissue specific and cutaneous lymphocyte antigen (CLA) is used to differentiate skin-homing T cells from gut-homing T cells expressing α4/β7 on their surface. To determine which of these cell types produce IL-31, CLA+ T cells were isolated from total T cells, activated and conditioned media was collected for the IL-31 bioassay. To do this, total T cells were isolated and then incubated on ice for 20 minutes in 1 mL of a 1:50 dilution of anti-CLA-FITC antibody (PharMingen). Cells were then washed, resuspended in MACS buffer and incubated with anti-FITC microbeads (Miltenyi Biotec) for 15 minutes at +4° C. The cells were then washed, resuspended and magnetically separated over an LS column according to the manufacturer's instructions. The labeled T cells were later determined to be >80% pure while the CLA-depleted T cells were >98% CLA−. Both CLA+ and CLA− T cells were collected and cultured concurrently.
- To activate the CD45RA+ and CD45RO+ T cell subsets, cells were cultured overnight in 24-well tissue culture plates pretreated with 2.0 μg/mL anti-CD3 antibody (Southern Biotechnology). The cells were plated at a concentration of 2.5×106 cells/mL in tissue culture media (RPMI, 5% fetal bovine serum, L-Glutamine and Sodium Pyruvate (all Gibco)) supplemented with 2.0 μg/mL anti-CD28 (Southern Biotechnology) and placed in a +37° C. incubator. After four hours, half of the wells were harvested, cells pelleted and conditioned media frozen at −20° C. until time of IL-31 bioassay.
- The CLA+ and CLA− T cell subsets were activated similarly in 48-well tissue culture plates that were pretreated with 2.0 μg/mL anti-CD3 antibody (Southern Biotechnology). The cells were activated for 16 hours or 24 hours in a +37° C. incubator at a concentration of 6.25×105 cells/mL. Samples were harvested, cells pelleted and conditioned media frozen at −20° C. until time of IL-31 bioassay. For suboptimal activation, CLA+ T cells were cultured in plates pre-treated with 0.5 ug/ml of anti-CD3 antibody.
- Human IL-31 Bioassay Protocol:
- BAF3 cells transfected with hIL-31RA, hOSMRbeta, and KZ134 were grown to 5×105 and 1×106 cells/mL. Cells were washed with assay media (RPMI 1640, 10% FBS, L-Glutamine, Sodium Pyruvate, and Pen/Strep (all Gibco)) and resuspended at 3×105 cell/mL in assay medium. In a 96-well opaque plate, hIL-31 standards were titered in duplicate from 600 pg/mL to 9.38 pg/mL in assay medium via a 100 μL/well, 1:2 serial dilution. Quality control standards were added in duplicate to the plate at 350 pg/mL and 35 pg/mL in 100 μL. Test samples were often diluted 1:2 or 1:4 and added in duplicate to the sample wells. 100 μL of the washed BAF3 cells were then added to each well for a final concentration of 3×104 cells/well. The plate was then incubated for 16-24 hours at +37° C. in a 5% CO2 incubator. The plate was then centrifuged at 1200 RPM for 5 minutes, media flicked off and 25 μL/well of lysis buffer (Promega) added to each well. After 10 minutes the plate was read on a luminometer (Berthold). The luminometer added 40 μL/well of luciferase substrate mix (Promega) and integrated the luminescence for a period of 4 seconds. Luminescence values were exported to a spreadsheet where they were analyzed and converted into picograms of IL-31 per 106 cells per mL of volume. The data is summarized in Table 1.
- Results of IL-31 Bioassay:
- The results from the CD45RA+ and the CD45RO+ T cell samples revealed that IL-31 was primarily produced by activated CD45RO+ memory T cells. The CD45RA+ and CD45RO+ T cells from both donors produced no detectable IL-31 when unstimulated. However, the CD45RO+ samples from both donors #3 and #4 generated significant levels of IL-31 following a 24 hour activation with plate-bound anti-CD3 and soluble anti-CD28 (110.4 pg/106 cells/mL and 145.6 pg/106 cells/mL respectively). Conversely, when the CD45RA+ T cells from donors #3 and #4 were activated with anti-CD3 and anti-CD28, they produced very low amounts of IL-31 (13.1 pg/106 cells/mL and 12.7 pg/106 cells/mL respectively).
- The CLA+ and CLA− T cell samples revealed that IL-31 seems to be made almost entirely by activated CLA+ T cells. The CLA− population of T cells (which includes naïve T cells, α4/β7 gut-homing memory T cells, and tissue uncommitted T cells) from both donors generated no detectable levels of IL-31 regardless of time point or activation condition. The CLA+ T cells on the other hand, generated very high levels of IL-31 when stimulated with 2.0 μg/mL plate-bound anti-CD3 antibody. Donor #5 generated 1385.7 pg/106 cells/mL IL-31 by 16 hours and >1920 pg/106 cells/mL by 24 hours. Donor #6 generated 121.3 pg/106 cells/mL IL-31 at 16 hours and 328.9 pg/106 cells/mL IL-31 at 24 hours. These results clearly demonstrate that of the T cell subsets, IL-31 seems to be made specifically by cutaneous (CLA+) T cells under standard activation conditions.
-
TABLE 1 IL-31 IL-31 (pg/106 (pg/106 Donor# Cell Type Activation cells/mL) cells/mL) 6 hr 24 hr 3 CD45RA+ αCD3 + αCD28 Below Detection 13.1 3 CD45RO+ αCD3 + αCD28 8.6 110.4 4 CD45RA+ αCD3 + αCD28 6.7 12.7 4 CD45RO+ αCD3 + αCD28 11.9 145.6 16 hr 24 hr 5 CLA+ T Cells Unstimulated Below Detection Below Detection 5 CLA+ T Cells αCD3 1385.7 >1920 5 CLA− T Cells Unstimulated Below Detection Below Detection 5 CLA− T Cells αCD3 Below Detection Below Detection 6 CLA+ T Cells Unstimulated Below Detection Below Detection 6 CLA+ T Cells αCD3 121.3 328.9 6 CLA− T Cells Unstimulated Below Detection Below Detection 6 CLA− T Cells αCD3 Below Detection Below Detection - Method I
- BALB/c mice are painted on shaved mid-back with 25 μl of 0.5% DNFB dissolved (2,4, dinitro-fluoro-benzene, Sigma, St. Louis Mo.) in acetone:olive oil (4:1) solution using a pipettor. A vehicle control group receives 25 μl of acetone:olive oil only. After 5 days, mice are anaesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals are measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement. Mice are then challenged by applying 10 μl of 0.25% DNFB in acetone:olive oil (4:1) to both sides of each ear of all mice. Contact hyper-sensitivity is measured at 24 h and 48 h later as the difference between the right ear (challenged) and the left ear (unchallenged). All measurements are done with an engineer's micrometer. Background values are determined by the difference in ear swelling between the challenged and unchallenged ears of naive mice.
- Whole blood and serum for FACS and/or ELISA analysis are collected prior to sacrifice and ears are collected for histology.
- Method II (Induces Th2 Responses)
- BALB/c mice are painted on shaved mid-back with 100 μl of 0.5% FITC (fluorescein isothiocyanate) in a 1:1 solution of acetone/dibutyl phthalate (MSDS available using pipettor on days 1, 2 and 8. On day 13, mice are anaesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals are measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement. Mice are challenged by applying 25 ul of 0.5% FITC (in 1:1 acetone/dibutyl phthalate) to the dorsal surface of each ear. Contact hyper-sensitivity is measured at 24 h and 48 h later as the difference between the right ear (challenged) and the left ear (unchallenged). All measurements are done with an engineer's micrometer. Background values are determined by the difference in ear swelling between the challenged and unchallenged ears of naive mice. Whole blood and serum for FACS and/or ELISA analysis are collected prior to sacrifice and ears are collected for histology.
- Method III (Induces Th1 Responses)
- BALB/c mice are painted on shaved mid-back with 25 ul of 2% oxazalone (in 4:lacetone/olive oil) using pipettor. On day 7, mice are anaesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals are measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement. Mice are challenged by applying 8 ul of oxazalone to the dorsal surface of each ear. Contact hyper-sensitivity is measured at 24 h and 48 h later as the difference between the right ear (challenged) and the left ear (unchallenged). All measurements are done with an engineer's micrometer. Background values are determined by the difference in ear swelling between the challenged and unchallenged ears of naive mice. Whole blood and serum for FACS and/or ELISA analysis are collected prior to sacrifice and ears are collected for histology.
- Involvement of IL-31 in the initiation and perpetuation of contact hyper-sensitivity is tested using a neutralizing antibody against IL-31 both at the sensitization and challenge phases of the experiment.
- Methods I (Sensitization of NC/Nga Mice)
- Male NC/Nga mice were purchased from Charles River Laboratories, Japan. The mice were 4 weeks old on arrival and housed in SPF quarantine conditions for 4 weeks to acclimate. The mice were approximately 10-11 weeks old at the start of the antigen sensitization. Mice were anaesthetized with isofluorane and backs were shaved with electric clippers. Approximately 10 ug of Dermatophagoides pteronyssinus (Dp) (Indoor Biotechnologies, Charlottesville, Va., special order) extract was injected intradermally at the nape of the neck 3 times per week for 5 to 6 weeks until mice developed skin lesions. Control animals received 10 ul PBS intradermal injections 3 times per week. The Dp extract was prepared according to method by Matsuoka and colleagues. Matsuoka H., et al., Allergy: 58, 139 (2003). Briefly, 595 mg Dp lyophilized spent culture extract was dissolved in 12 mL sterile PBS (Gibco). Dp was mixed in a 50 mL Falcon tube on a shaking rocker for 30 minutes. The extract was spun for 10 minutes at 2000 rpm and the supernatant was collected and aliquoted into 1 mL cryovial tubes and stored at −20° C.
- Method II (Sensitization of DO11.10 Mice)
- DO11.10 transgenic mice were bred from an in-house colony and were between 9.5 and 14 weeks old at start of antigen sensitization. Twenty-four hours prior to epicutaneous sensitization mice were anaesthetized with isofluorane and the entire trunk (back and abdomen) of mice were shaved with electric clippers. The mice were then tape stripped with Elastin surgical tape (Johnson and Johnson) on the back. One cm2 sterile gauze patches were wetted with either 500 ug ovalbumin (Calbiochem 32467) or sterile PBS (Gibco) and adhered to left backside of mice with DuoDerm Extra Thin Dressing (ConvaTec 187932). The patch and dressing were then covered in a body wrap of the Elastin surgical tape so mice could not remove or destroy the patches. Patches were worn for 7 days and removed. The mice were rested for two weeks before having another round of epicutaneous sensitization. Mice received a total of three one-week sensitizations.
- Results
- Immunohistochemical analysis of IL-31RA expression in lesional and non-lesional skin from dust mite sensitized NC/Nga and OVA sensitized DO11.10 animals showed that IL-31RA is expressed by epidermal keratinocytes in mice, however no significant difference in levels of expression can be found between antigen sensitized versus PBS sensitized animals.
- Methods
- To generate a DTH response, mice were sensitized to antigen on day 0 by subcutaneous immunization at the base of the tail with 100 ug ovalbumin (OVA) in complete Freund's adjuvant (CFA, 50-100 μl total volume). One week later mice were anesthetized with isofluorane in an inhalation chamber and both ear pinnae of experimental and control animals were measured with an engineer's micrometer (Mitutoyo) to obtain a baseline measurement. Mice were challenged intradermally with 10 ug OVA in PBS in a total volume of 10 μl into the left ear pinnae, just below the skin without hitting any veins. As a control, mice also received an injection of 10 μl PBS in the right ear pinnae. In some cases, a separate control group given an i.d. injection of OVA in the ear may also be treated with topical corticosteroids as a positive control to inhibit the reaction. At 24 and 48 hr after challenge, mice were anesthetized and ear thickness was measured. Results were expressed as: Specific ear swelling=(24 hr measurement −0 hr measurement) for experimental ear−(24 hr measurement−0 hr measurement) for negative control ear. Induration, the hallmark of DTH, is detectable by 18 hours after injection of sensitized antigen and is maximal by 24-48 hours. The lag in the onset of palpable induration is the reason for naming the response “delayed type.”
- Results
- IL-31 transgenic mice were tested for DTH, however, due to an increase in ear thickness in un-challenged IL-31 transgenic animals, no statistically significant difference in DTH could be determined between IL-31 Tg animals compared to wildtype controls. IL-31RA knockout animals were also tested in a DTH response and no significant difference in the DTH response could be observed between receptor knockout and wildtype animals.
- Methods I (IL-31 Treatment of Capsaicin Pre-Treated Mice)
- Ten week old BALB/c animals (CRL) were anaesthetized and injected with a long-lasting analgesic agent, bupranorphine hydrochloride, subcutaneously at 0.1 mg/kg before injection of 0.25 ml of 4 mg/ml solution of capsaicin in 10% ethanol+10% Tween-80 in saline subcutaneously into scruff of neck. Animals were kept anaesthetized for at least 30 min following neurotoxin treatment. Forty-eight hours later, 14-day osmotic pumps were implanted subcutaneously for continuous delivery of 20 ug/day of IL-31 for 14 days. Mice were monitored daily for 6 days for alopecia and pruritis using the following criteria: 0=no scratching, animal appears normal, 1=thinning of coat in small areas, scratching noted, 2=minor hair loss (small patches), scratching, 3=moderate hair loss, scratching, and 4=severe hair loss, excessive scratching.
- Results demonstrated that while non-capsaicin-treated mice showed a mean scratch/hairloss score of 2.625 following three days of IL-31 delivery, capsaicin-treated mice showed a significantly lower score of 1. Thus mice treated with capsaicin prior to IL-31 delivery showed both a delay in incidence of scratching and hairloss and a lower score in the intensity of scratching and hairloss over the six days of the experiment. These data suggest that IL-31 does induce some neuronal component that contributes to the alopecia and pruritis induced by IL-31. Therefore, neutralization of IL-31 may decrease the incidence and intensity of itch, and therefore dermatitis, in patients suffering from skin disorders that involve itch.
- Method II (IL-31 Treatment of Tac1 Gene Deficient Mice)
- Mice that are homozygous null for the Tac1 gene express no detectible substance P or neurokinin A. These mice have significantly reduced nociceptive pain responses to moderate to intense stimuli and are therefore a useful tool for studying the contribution of tachykinin peptides to pain/itch processing and inflammatory disease states. Twelve week old, Tac1 knockout mice were implanted with 14-day osmotic pumps delivering 1 ug/day of IL-31 protein and observed daily for alopecia and pruritis using the following criteria: 0=no scratching, animal appears normal, 1=thinning of coat in small areas, scratching noted, 2=minor hair loss (small patches), scratching, 3=moderate hair loss, scratching, and 4=severe hair loss, excessive scratching.
- Results of this study show that Tac1 deficient mice were less susceptible to IL-31 induced scratching/hairloss compared to wildtype control mice. While 100% (10/10) of wildtype mice had developed evidence of scratching and hairloss by day 6 of IL-31 treatment, only 33.3% (2/6) Tac1 deficient mice were showing signs of scratching and hairloss at the same time-point. These data show that IL-31 induces a neuronal component that contributes to the scratch/hairloss phenotype in IL-31-treated mice and neutralization of IL-31 may decrease the incidence and intensity of scratching in the context of dermatitis.
- Method III (Effect of Administration of IL-31 Neutralizing Antibody on IL-31 Treated Mice)
- Normal female BALB/c mice (CRL) approximately 8 to 12 weeks old were implanted subcutaneously with 14-day osmotic pumps (Alzet, #2002) delivering 1 ug/day mIL-31. Groups of mice received intraperitoneal (i.p.) injections of rat anti-mouse IL-31 monoclonal antibody 10 mg/kg (200 ug/mouse) twice weekly starting 1 week prior to IL-31 delivery. Control groups of mice received i.p. injections of vehicle (PBS/0.1% BSA) with the identical dosing schedules. Mice were scored daily for alopecia and pruritis using the following criteria: 0=no scratching, animal appears normal, 1=thinning of coat in small areas, scratching noted, 2=minor hair loss (small patches), scratching, 3=moderate hair loss, scratching, and 4=severe hair loss, excessive scratching.
- In all experiments, mice treated with rat anti-mIL-31 mAb had a delay in onset of symptoms of approximately 5 to 7 days and a lower overall score for alopecia and pruritis. All groups of mAb treated mice (regardless of dose frequency or concentration) developed alopecia and pruritis similar to control mice by 13 day of the study. These data suggest that neutralization of IL-31 can delay the onset of the scratch/hairloss response induced by IL-31.
- Uninvolved psoriatic, atopic dermatitis and normal skin were tested for the IL-31 ligand by IHC. Positive control cells consisted of BHK cells transfected with IL-31. Negative controls performed included: (1) un-transfected BHK cells, (2) staining representative tissues and cells with protein A purified Normal Rabbit serum and detecting antibody binding as usual. Antibody reagent was E5758 (Rabbit anti-huIL-31 CEE, Aff. Purified at 1.0 mg/ml). Control cells included C02-6020: BHK cells expressing zcytor17 Lig hu-CEE/21, and a BHK wild type. Tissues tested included acute atopic dermatitis skin samples, chronic atopic dermatitis skin samples, unaffected area skin samples, and normal control skin samples and other in-house control samples.
- The cells and tissues described above were fixed overnight in 10% NBF and embedded in paraffin using standard techniques.
- Five μM sections were baked at 61° C. for 30 min for tissue adhesion. Slides were subsequently dewaxed in 3×5′ in xylene and rehydrated through graded alcohols as follows: 2×2′ in 100% EtOH, 2×2′ in ×95% EtOH, 1×2′ in 70% EtOH. Slides were rinsed in dH20, and then heat induced epitope retrieval (HIER) was performed for 20 minutes under steam followed by 20 minutes cooling to RT in 10 mM Tris, 1 mM EDTA, pH 9.0
- Slides were loaded onto a DakoCytomation Autostainer. Slides were rinsed with TBS/Tween buffer (TBST), prepared as recommend by manufacturer. Endogenous biotin was blocked with a 10 minute incubation in avidin solution, washed in TBST followed by a 10 minute incubation in biotin solution. Slides were washed in TBST. A protein block (PBSB) (0.5% Blocking Powder in PBS, Perkin Elmer NEL700001KT.) was applied for 30 minutes and rinsed off slides. The primary antibody was diluted to 500 ng/ml and was applied for 60 minutes in ChemMate Antibody Dilution Buffer (part# ADB250, Ventana Medical systems).
- Tissues washed twice in TBST, and then incubated 45 minutes in biotinylated Goat anti-Rabbit Ab, 750 ng/ml in PBSB (catalog # BA-1000, Vector Labs). Slides washed twice in TBST. Vectastain Elite ABC Reagent (catalog# PK-7100, Vector Labs) was incubated for 45 minutes. Slides washed twice in TBST. Signals were developed with DAB+ (catalog# K-3468, DakoCytomation) for 10 minutes at room temperature. Tissue slides were then counterstained in hematoxylin (catalog# H-3401 Vector Labs), dehydrated and coverslipped in VectorMount (catalog# H-5000, Vector Labs).
- Results
- Cell Controls:
- BHK cells transfected with IL-31 was positively stained with IL-31 antibody E5758 while un-transfected cells was negative for this antibody. The same transfected and un-transfected cells were negative with anti-rabbit sera.
- 2) Atopic Dermatitis Skin Analysis:
- The staining pattern for IL31 in the AD skin samples is identical to that of psoriasis skins reported previously: keratinocyte and CD3 positive T-cells stained negative for IL31. A weak but rather uniform staining of the epithelial cells in the secretory portion of the sweat glands was present, but a strong signal was observed in the inner layer of epithelium in the duct portion. Sebaceous gland was positive for IL31. There was no difference in the IL31 staining between AD and normal skin.
- Immunohistochemical (IHC) staining of uninvolved psoriatic, atopic dermatitis and normal skin showed strong staining of IL-31 in the holocrine secretion of the sebaceous glands. Considering the phenotype of IL 31 transgenic mice, it is interesting to note that the sebaceous glands originate as an epithelial bud from the outer root sheath of hair follicles. In addition to sebaceous glands weak but rather uniform staining of IL-31 was observed in the epithelial cells in the secretory portion of the sweat glands and a strong signal in the inner layer of epithelium was observed in the duct portion of sweat glands.
- Uninvolved psoriatic, atopic dermatitis and normal skin were tested for the IL-31RA by IHC. Positive control cells consisted of BHK cells dual transfected with IL-31RA and OSMR. Negative controls performed included: (1) un-transfected BHK cells, (2) staining representative tissues and cells with protein A purified Normal Rabbit serum and detecting antibody binding as usual. Antibody reagent was E6292 (Rabbit anti-huIL-31RAs-CEE v.4 at 1.33 mg/ml). Control cells included C02-5117 BHK cells expressing human IL-31RA and human OSMR (Total cells in the pellet: 3.9×106, vitality was >90%) and C04-1587: BHK wild type (Total cells in the pellet: 5×106). Other tissues examined included: 5 Acute atopic dermatitis skin samples, 10 Chronic atopic dermatitis skin samples, 10 Unaffected area skin samples, Normal control skin samples, and other in-house skin samples.
- The cells and tissues described above were fixed overnight in 10% NBF and embedded in paraffin using standard techniques.
- Five μM sections were baked at 61° C. for 30 min for tissue adhesion. Slides were subsequently dewaxed in 3×5′ in xylene and rehydrated through graded alcohols as follows: 2×2′ in 100% EtOH, 2×2′ in ×95% EtOH, 1×2′ in 70% EtOH. Slides were rinsed in dH20, and then heat induced epitope retrieval (HIER) was performed for 20 minutes under steam followed by 20 minutes cooling to RT in 10 mM Tris, 1 mM EDTA, pH 9.0
- Slides were loaded onto a DakoCytomation Autostainer. Slides were rinsed with TBS/Tween buffer (TBST), prepared as recommend by manufacturer. Endogenous biotin was blocked with a 10-minute incubation in avidin solution, washed in TBST followed by a 10-minute incubation in biotin solution. Slides were washed in TBST. A protein block (PBSB) (0.5% Blocking Powder in PBS, Perkin Elmer NEL700001KT.) was applied for 30 minutes and rinsed off slides. Primary antibodies diluted from 665 ng/ml to 1330 ng/ml for IL31RA were applied for 60 minutes in ChemMate Antibody Dilution Buffer (part# ADB250, Ventana Medical systems).
- Tissues were washed twice in TBST, and then incubated 45 minutes in biotinylated Goat anti-Rabbit Ab, 750 ng/ml in PBSB (catalog # BA-1000, Vector Labs). Slides were washed twice in TBST. Vectastain Elite ABC Reagent (catalog# PK-7100, Vector Labs) was incubated for 45 minutes. Slides were washed twice in TBST. Signals were developed with DAB+(catalog# K-3468, DakoCytomation) for 10 minutes at room temperature. Tissue slides were then counterstained in hematoxylin (catalog# H-3401 Vector Labs), dehydrated and coverslipped in VectorMount (catalog# H-5000, Vector Labs).
- Results are shown in Table 2.
-
TABLE 2 Results of IHC for IL-31RA in Skin Biopsies from Acute and Uninvolved AD Compared to Normal Volunteers IL-31RA IHC CASE ID SCORE* CD3 IHC SCORE* AD-1 2-3 0-1 AD-2 2-3 2 AD-3 2-3 1-2 AD-4 3 1 AD-5 2 2 UAD-1 1-2 1 UAD-2 1 0-1 UAD-3 ND ND UAD-4 ND ND UAD-5 1-2 0-1 UAD-6 2-3 ND UAD-7 2 1 UAD-8 1 1 UAD-9 1-2 1 UAD-10 2 ND Normal-1 1 0-1 Normal-2 0-1 0-1 Normal-3 1 0-1 Abbreviations: AD: atopic dermatitis; UAD: uninvolved AD; ND: Not Done *IHC signal was scored from 0 (no signal) to 4 (intense signal) - There was a slight up regulation of IL31RA in the epidermis of AD skin samples. Possibly a small percentage of CD3 positive T-cells were positive for IL31RA in the AD skins. There were CLA positive cells in all skin samples tested. AD skins may have more CLA positive cells than that of the normal or UAD samples.
- IL-31RA was also expressed in the epithelial cells of eccrine sweat glands with the cuboidal epithelial cells in the secretory portion of the eccrine glands demonstrating slightly higher level of IL-31RA protein compared to the duct portion.
- Collectively, these data demonstrate that IL-31RA is expressed by epidermal keratinocytes from both control volunteers and AD patients. However, the levels of IL-31RA expressed on keratinocytes from AD skin biopsies were higher than the levels observed in skin biopsies from normal controls, indicating a potential for increased responsiveness to IL-31 in the context of AD.
- IL-31RA was also found expressed on a subset of perivascular infiltrating cells present in skin biopsies from AD patients but was not present in control skin biopsies. These IL-31RA+ cells were recognized by an antibody specific for the tissue macrophage marker CD68, indicating these cells were skin-infiltrating tissue macrophages.
- The presence of skin infiltrating T cells is a distinguishing feature in skin biopsies from AD patients compared to normal individuals. Since IL-31 is a T cell associated cytokine, the expression of IL-31 in skin-infiltrating T cells in tissue biopsies from AD patients was examined. First, the presence of increased numbers of CD3+ T cells in skin tissue biopsies from AD patients compared to normal individuals was confirmed by IHC. See Table 2. Next, laser capture microscopy was used to specifically isolate skin infiltrating cells for analysis of IL-31 mRNA by RT-PCR. IL-31 mRNA was expressed by skin infiltrating cells from acute AD patients. In normal tissues, infiltrating cells are not normally found and therefore could not be tested. However, the epidermal keratinocyte layer, which is present in both AD and normal skin, was analyzed for IL-31 mRNA expression and lower levels of IL-31 mRNA were found in normal samples compared to the epidermal keratinocyte layer of AD samples. Semi-quantitative analysis of IL-31 mRNA expression compared to an internal control gene (HPRT) showed that although IL-31 mRNA levels were not significantly different between AD and normal samples, there was a trend towards higher IL-31 expression in skin from AD patients.
- Analysis of skin biopsies confirmed that the infiltrating CD3+ T cells in the skin, which express IL-31 mRNA, express the skin-homing marker cutaneous lymphocyte antigen (CLA). Of the total T cell population in normal human peripheral blood, IL-31 expression was found to be largely restricted to CD45RO+ memory/effector cells as opposed to the CD45RA+ naïve T cell population.
- In order to determine if IL-31 production was associated with CLA+ skin-homing T cells, CLA+ and CLA− T cells were isolated from peripheral blood of patients diagnosed with AD and control volunteers and compared IL-31 mRNA and protein levels following anti-CD3 plus anti-CD28 stimulation. Our results indicate that IL-31 mRNA was significantly elevated in CLA+ T cells from both AD and normal individuals at both 4 h (p0.0087 and p0.0022 CLA+ compared to CLA− for AD and normal, respectively) and 24 h (p0.0022 CLA+ compared to CLA− for both AD and normal samples) post stimulation. Analysis of IL-31 protein levels in culture supernatants confirmed that IL-31 was produced predominantly by CLA+ T cells as there was no detectible IL-31 in culture supernatants from CLA− T cells from both AD and control individuals. There were no significant differences in IL-31 levels between AD and normal patients. We also analysed the production of IL-31 by peripheral blood T cells that express other tissue-specific homing markers, such as the gut-specific homing marker α4β7, from normal volunteers. Comparison of the IL-31 levels produced by CLA+ T cells and α4β7+ cells demonstrated CLA+ T cells preferentially produce IL-31 compared to the α4β7+ cells (average of 34.5 pg/ml and 14.42 pg/ml IL-31, respectively).
- Although both AD patients and normal controls have circulating CLA+ T cells that express IL-31 upon activation, CLA+ T cells from AD patients are reported to exist in a more activated state compared to cells from normal individuals. Consequently, the threshold of stimulation required for the production of IL-31 by CLA+ T cells may differ between dermatitis patients and control subjects. To test this hypothesis, we stimulated CLA+ T cells from AD patients and control individuals with sub-optimal concentrations of anti-CD3 in the absence of anti-CD28 and analyzed the production of IL-31 in culture supernatants at 24 h after stimulation. Our results demonstrate that circulating CLA+ T cells from some AD patients produce higher levels of IL-31 compared to cells from normal individuals in this study with maximum levels reaching 1200 pg/mL, whereas maximal detected levels in normal CLA+ supernatants was only 400 pg/ml and maximal detected levels for psoriasis patients was 73 pg/ml at suboptimal concentrations of anti-CD3 stimulation. Five of eleven AD patients showed IL-31 levels below the limit of detection of our assay suggesting there might be a subset of AD patients where IL-31 is produced at low levels. This may reflect variations in the stage of disease of our study population. Nevertheless, more than half of the AD patients showed a trend towards higher IL-31 levels compared to psoriasis patients and normal individuals following suboptimal stimulation with anti-CD3. Since more CLA+ T cells are localized in skin of AD patients as compared to normal individuals, our studies suggest that there is an increased potential for IL-31 activity in the AD skin micro-environment. Thus, this study may suggest a subpopulation of AD patients, which have more activated CLA+ T cells producing IL-31.
- Method I
- Six-week old male NC/Nga mice (CRL Japan) were sensitized intradermally with 50 μg dust mite extract (D. pteronyssinus, Indoor Biotechnologies) three times a week on the back and scored for AD-like lesions. After 5 weeks of sensitization the mice were euthanized and the right ears were excised and placed into a single well of a 48-well culture dish (Corning) supplemented with RPMI+2% FBS (GIBCO Invitrogen). Plates were placed in 5% CO2 humidity controlled incubators. Supernatants were collected after 24 hours and frozen at −20° C. until further analysis.
- Method II
- Twelve-week old female NC/Nga mice (CRL Japan) were sensitized intradermally with 10 μg SEB (Toxin Technology) in the ear and on the back three times per week. The mice were scored for AD-like lesions. After 5 weeks of sensitization the mice were euthanized and 6 mm biopsy punches were taken from the injected ear of each mouse and placed into a single well of a 48-well culture dish supplemented with RPMI+2% FBS. Plates were placed in 5% CO2 humidity controlled incubators. Supernatants were collected after 24 hours and frozen at −20° C. until further analysis.
- Groups of mice in both studies were treated with either a rat anti-mouse IL-31 monoclonal antibody at 10 mg/kg or vehicle, intraperitoneally two times each week starting after 1 to 2 weeks of sensitization.
- TARC and MDC concentrations in the 24-hour supernatant samples were measured by conventional ELISA (R&D Systems).
- TARC and MDC concentrations were lower in ear supernatants from anti-IL-31 treated mice compared to control mice in both studies, however, these results were not statistically significant when analyzed by ANOVA, probably due to small sample size. When the data from both experiments is combined and analyzed there is a statistically significant difference between treated groups.
Claims (5)
1. A method of treating a patient with a skin disorder selected from the group consisting of:
a) prurigo nodularis;
b) Cutaneous T cell Lymphoma;
c) Bullous pemphigoid;
d) Vitiligo;
e) Acne Rosacea; and
f) Scleroderma;
wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising an anti-Interleukin-31RA (IL-31RA) antibody or an antigen-binding fragment thereof and a pharmaceutically acceptable carrier to the patient, wherein the anti-IL-31RA antibody or antigen-binding fragment binds amino acid residues 20-519 of SEQ ID NO:6.
2. The method of claim 1 , wherein the anti-IL-31RA antibody or antigen-binding fragment is neutralizing.
3. The method of claim 1 , wherein the Fc region of the anti-IL-31RA antibody is IgG, IgA, IgD, IgM or IgE.
4. The method of claim 1 , wherein the Fc region of the anti-IL-31RA antibody is IgG.
5. The method of claim 1 , wherein the anti-IL-31RA antibody or an antigen-binding fragment thereof is humanized.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/411,640 US20170137525A1 (en) | 2005-02-14 | 2017-01-20 | Methods of treating skin disorders using an anti-il-31ra antibody |
US15/615,567 US20170275369A1 (en) | 2005-02-14 | 2017-06-06 | Methods of treating skin disorders using anti-il-31ra antibodies |
US15/839,362 US20180094068A1 (en) | 2005-02-14 | 2017-12-12 | Methods of treating skin disorders using anti-il-31ra antibodies |
US15/960,070 US10611846B2 (en) | 2005-02-14 | 2018-04-23 | Methods of treating skin disorders using anti-IL-31RA antibodies |
US16/804,475 US11312779B2 (en) | 2005-02-14 | 2020-02-28 | Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65328305P | 2005-02-14 | 2005-02-14 | |
US69486705P | 2005-06-29 | 2005-06-29 | |
US71676105P | 2005-09-13 | 2005-09-13 | |
US11/353,451 US20060182743A1 (en) | 2005-02-14 | 2006-02-14 | Methods of treating skin disorders using an IL-31RA antagonist |
US12/404,162 US7871618B2 (en) | 2005-02-14 | 2009-03-13 | Methods of treating skin disorders using an IL-31RA antagonist |
US12/986,707 US9139651B2 (en) | 2005-02-14 | 2011-01-07 | Methods of treatment using IL-31RA |
US14/829,711 US20150344581A1 (en) | 2005-02-14 | 2015-08-19 | Methods of treating skin disorders using il-31ra antagonist |
US15/411,640 US20170137525A1 (en) | 2005-02-14 | 2017-01-20 | Methods of treating skin disorders using an anti-il-31ra antibody |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/829,711 Continuation US20150344581A1 (en) | 2005-02-14 | 2015-08-19 | Methods of treating skin disorders using il-31ra antagonist |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/615,567 Continuation US20170275369A1 (en) | 2005-02-14 | 2017-06-06 | Methods of treating skin disorders using anti-il-31ra antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170137525A1 true US20170137525A1 (en) | 2017-05-18 |
Family
ID=36572470
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/353,451 Abandoned US20060182743A1 (en) | 2005-02-14 | 2006-02-14 | Methods of treating skin disorders using an IL-31RA antagonist |
US12/404,162 Active US7871618B2 (en) | 2005-02-14 | 2009-03-13 | Methods of treating skin disorders using an IL-31RA antagonist |
US12/986,707 Active 2029-05-02 US9139651B2 (en) | 2005-02-14 | 2011-01-07 | Methods of treatment using IL-31RA |
US14/829,711 Abandoned US20150344581A1 (en) | 2005-02-14 | 2015-08-19 | Methods of treating skin disorders using il-31ra antagonist |
US15/411,640 Abandoned US20170137525A1 (en) | 2005-02-14 | 2017-01-20 | Methods of treating skin disorders using an anti-il-31ra antibody |
US15/615,567 Abandoned US20170275369A1 (en) | 2005-02-14 | 2017-06-06 | Methods of treating skin disorders using anti-il-31ra antibodies |
US15/839,362 Abandoned US20180094068A1 (en) | 2005-02-14 | 2017-12-12 | Methods of treating skin disorders using anti-il-31ra antibodies |
US15/960,070 Active US10611846B2 (en) | 2005-02-14 | 2018-04-23 | Methods of treating skin disorders using anti-IL-31RA antibodies |
US16/804,475 Active 2026-04-30 US11312779B2 (en) | 2005-02-14 | 2020-02-28 | Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/353,451 Abandoned US20060182743A1 (en) | 2005-02-14 | 2006-02-14 | Methods of treating skin disorders using an IL-31RA antagonist |
US12/404,162 Active US7871618B2 (en) | 2005-02-14 | 2009-03-13 | Methods of treating skin disorders using an IL-31RA antagonist |
US12/986,707 Active 2029-05-02 US9139651B2 (en) | 2005-02-14 | 2011-01-07 | Methods of treatment using IL-31RA |
US14/829,711 Abandoned US20150344581A1 (en) | 2005-02-14 | 2015-08-19 | Methods of treating skin disorders using il-31ra antagonist |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/615,567 Abandoned US20170275369A1 (en) | 2005-02-14 | 2017-06-06 | Methods of treating skin disorders using anti-il-31ra antibodies |
US15/839,362 Abandoned US20180094068A1 (en) | 2005-02-14 | 2017-12-12 | Methods of treating skin disorders using anti-il-31ra antibodies |
US15/960,070 Active US10611846B2 (en) | 2005-02-14 | 2018-04-23 | Methods of treating skin disorders using anti-IL-31RA antibodies |
US16/804,475 Active 2026-04-30 US11312779B2 (en) | 2005-02-14 | 2020-02-28 | Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions |
Country Status (8)
Country | Link |
---|---|
US (9) | US20060182743A1 (en) |
EP (1) | EP1858924A1 (en) |
JP (1) | JP2008530132A (en) |
AU (1) | AU2006214404B2 (en) |
CA (1) | CA2594490A1 (en) |
IL (2) | IL184371A (en) |
MX (1) | MX2007009718A (en) |
WO (1) | WO2006088855A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10611846B2 (en) | 2005-02-14 | 2020-04-07 | Zymogenetics, Inc. | Methods of treating skin disorders using anti-IL-31RA antibodies |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2339843T3 (en) * | 1999-06-02 | 2010-05-26 | Chugai Seiyaku Kabushiki Kaisha | PROTEIN RECEIVING HEMATOPOYETINA NOVEDOSA, NR10. |
EP1221482B1 (en) * | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
US20030096339A1 (en) | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
US9738700B2 (en) | 2002-01-18 | 2017-08-22 | Zymogenetics Inc. | ZCYTOR17 heterodimeric cytokine receptor |
WO2003060090A2 (en) | 2002-01-18 | 2003-07-24 | Zymogenetics, Inc. | Novel cytokine zcytor17 ligand |
EP2338910B1 (en) * | 2002-01-18 | 2015-07-08 | ZymoGenetics, Inc. | Cytokine receptor Zcytor17 multimers |
MX2007009471A (en) | 2005-02-14 | 2008-02-15 | Zymogenetics Inc | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells. |
US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
AU2006244180B2 (en) | 2005-05-06 | 2012-03-01 | Zymogenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
AU2007254715B2 (en) | 2005-05-06 | 2013-08-29 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
CA2647846C (en) * | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
RU2511406C2 (en) * | 2006-06-08 | 2014-04-10 | Чугаи Сейяку Кабусики Кайся | Preventive and therapeutic agent for inflammatory disease |
CN103044550A (en) | 2006-09-01 | 2013-04-17 | 津莫吉尼蒂克斯公司 | IL-31 monoclonal antibodies and methods of use |
CA2672739A1 (en) * | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc. | Methods of using il-31 to treat airway hyper-responsiveness and asthma |
CA3066453C (en) | 2007-09-26 | 2022-01-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
JP5334319B2 (en) * | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Method for modifying isoelectric point of antibody by amino acid substitution of CDR |
RU2541780C2 (en) * | 2007-12-05 | 2015-02-20 | Чугаи Сейяку Кабусики Кайся | Therapeutic agent for itching |
KR101840994B1 (en) | 2007-12-05 | 2018-03-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-NR10 antibody and use thereof |
TR201802202T4 (en) | 2007-12-07 | 2018-03-21 | Merck Serono Sa | IL-31 specific humanized antibody molecules. |
EP4238993A3 (en) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
JP5139517B2 (en) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | Anti-NR10 antibody and use thereof |
KR20160062207A (en) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | Anti-NR10 antibody and use thereof |
JP2010210772A (en) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | Method of manufacturing liquid crystal display device |
WO2010107109A1 (en) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | Antibody constant region variant |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
TWI812066B (en) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | Antibody having calcium-dependent antigen-binding ability |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
US10501802B2 (en) * | 2013-04-30 | 2019-12-10 | Universite De Montreal | Biomarkers for acute myeloid leukemia |
NZ713636A (en) | 2013-05-30 | 2022-07-01 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins |
TW201537175A (en) * | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | Method for predicting response of patient with pruritic disease to IL-31 antagonist therapy |
JP5954916B1 (en) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | A pharmaceutical composition for preventing and / or treating atopic dermatitis, comprising an IL-31 antagonist as an active ingredient |
TW202327654A (en) | 2015-04-14 | 2023-07-16 | 日商中外製藥股份有限公司 | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
NZ747512A (en) * | 2016-04-27 | 2023-05-26 | Benchmark Animal Health Ltd | Treatment of canine atopic dermatitis |
EP3538558A4 (en) | 2016-11-09 | 2020-07-15 | North Carolina State University | TREATMENT OF ALLERGIC DISEASES WITH A CHIMERAL PROTEIN |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
JP2021512917A (en) * | 2018-02-09 | 2021-05-20 | ガルデルマ ホールディング エスエー | Nemolizumab in the treatment of atopic dermatitis with moderate to severe scratches |
AU2019234220A1 (en) | 2018-03-16 | 2020-09-10 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
MA52011A (en) | 2018-03-16 | 2021-01-20 | Zoetis Services Llc | PEPTIDIC VACCINES AGAINST INTERLEUKIN-31 |
WO2019183437A1 (en) | 2018-03-23 | 2019-09-26 | North Carolina State University | Methods and compositions for antibody to high affinity receptor for ige |
WO2020051498A1 (en) * | 2018-09-06 | 2020-03-12 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of viral infections |
EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
US20230391878A1 (en) | 2020-09-01 | 2023-12-07 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
TW202221039A (en) | 2020-10-19 | 2022-06-01 | 美商碩騰服務公司 | Antibodies to canine and feline oncostatin m receptor beta and uses thereof |
US20220411518A1 (en) * | 2021-04-07 | 2022-12-29 | Galderma Holding S.A. | Treatments for prurigo nodularis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000721A2 (en) * | 2000-06-26 | 2002-01-03 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
US20030215838A1 (en) * | 2002-01-18 | 2003-11-20 | Sprecher Cindy A. | Cytokine receptor zcytor17 multimers |
US7064186B2 (en) * | 2002-01-18 | 2006-06-20 | Zymogenetics, Inc. | Cytokine zcytor17 ligand |
US7871618B2 (en) * | 2005-02-14 | 2011-01-18 | Zymogenetics, Inc. | Methods of treating skin disorders using an IL-31RA antagonist |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2339843T3 (en) | 1999-06-02 | 2010-05-26 | Chugai Seiyaku Kabushiki Kaisha | PROTEIN RECEIVING HEMATOPOYETINA NOVEDOSA, NR10. |
EP1309620A2 (en) | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
EP1326978A2 (en) | 2000-10-06 | 2003-07-16 | Immunex CorporatioN | Hematopoietin receptors hpr1 and hpr2 |
WO2002077230A1 (en) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Nr10 splicing variants |
ATE431406T1 (en) | 2002-02-25 | 2009-05-15 | Genentech Inc | NEW TYPE 1 CYTOKINE RECEPTOR GLM-R |
MX2007009471A (en) | 2005-02-14 | 2008-02-15 | Zymogenetics Inc | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells. |
AU2007254715B2 (en) | 2005-05-06 | 2013-08-29 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
AU2006244180B2 (en) | 2005-05-06 | 2012-03-01 | Zymogenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
CN103044550A (en) | 2006-09-01 | 2013-04-17 | 津莫吉尼蒂克斯公司 | IL-31 monoclonal antibodies and methods of use |
-
2006
- 2006-02-14 WO PCT/US2006/005148 patent/WO2006088855A1/en active Application Filing
- 2006-02-14 MX MX2007009718A patent/MX2007009718A/en active IP Right Grant
- 2006-02-14 US US11/353,451 patent/US20060182743A1/en not_active Abandoned
- 2006-02-14 AU AU2006214404A patent/AU2006214404B2/en not_active Ceased
- 2006-02-14 CA CA002594490A patent/CA2594490A1/en not_active Abandoned
- 2006-02-14 JP JP2007555338A patent/JP2008530132A/en active Pending
- 2006-02-14 EP EP06720729A patent/EP1858924A1/en not_active Withdrawn
-
2007
- 2007-07-03 IL IL184371A patent/IL184371A/en not_active IP Right Cessation
-
2009
- 2009-03-13 US US12/404,162 patent/US7871618B2/en active Active
-
2010
- 2010-08-19 IL IL207688A patent/IL207688A0/en unknown
-
2011
- 2011-01-07 US US12/986,707 patent/US9139651B2/en active Active
-
2015
- 2015-08-19 US US14/829,711 patent/US20150344581A1/en not_active Abandoned
-
2017
- 2017-01-20 US US15/411,640 patent/US20170137525A1/en not_active Abandoned
- 2017-06-06 US US15/615,567 patent/US20170275369A1/en not_active Abandoned
- 2017-12-12 US US15/839,362 patent/US20180094068A1/en not_active Abandoned
-
2018
- 2018-04-23 US US15/960,070 patent/US10611846B2/en active Active
-
2020
- 2020-02-28 US US16/804,475 patent/US11312779B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000721A2 (en) * | 2000-06-26 | 2002-01-03 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
US20030215838A1 (en) * | 2002-01-18 | 2003-11-20 | Sprecher Cindy A. | Cytokine receptor zcytor17 multimers |
US7064186B2 (en) * | 2002-01-18 | 2006-06-20 | Zymogenetics, Inc. | Cytokine zcytor17 ligand |
US7871618B2 (en) * | 2005-02-14 | 2011-01-18 | Zymogenetics, Inc. | Methods of treating skin disorders using an IL-31RA antagonist |
US20150344581A1 (en) * | 2005-02-14 | 2015-12-03 | Zymogenetics, Inc. | Methods of treating skin disorders using il-31ra antagonist |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10611846B2 (en) | 2005-02-14 | 2020-04-07 | Zymogenetics, Inc. | Methods of treating skin disorders using anti-IL-31RA antibodies |
US11312779B2 (en) | 2005-02-14 | 2022-04-26 | Zymogenetics, Inc. | Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions |
Also Published As
Publication number | Publication date |
---|---|
IL184371A (en) | 2010-12-30 |
EP1858924A1 (en) | 2007-11-28 |
WO2006088855A1 (en) | 2006-08-24 |
AU2006214404A1 (en) | 2006-08-24 |
US20170275369A1 (en) | 2017-09-28 |
US20180094068A1 (en) | 2018-04-05 |
US20150344581A1 (en) | 2015-12-03 |
JP2008530132A (en) | 2008-08-07 |
US7871618B2 (en) | 2011-01-18 |
US20180244790A1 (en) | 2018-08-30 |
US20090252730A1 (en) | 2009-10-08 |
US20200239581A1 (en) | 2020-07-30 |
MX2007009718A (en) | 2007-09-26 |
CA2594490A1 (en) | 2006-08-24 |
US20060182743A1 (en) | 2006-08-17 |
IL184371A0 (en) | 2007-10-31 |
US11312779B2 (en) | 2022-04-26 |
US20110117052A1 (en) | 2011-05-19 |
US10611846B2 (en) | 2020-04-07 |
AU2006214404B2 (en) | 2012-03-08 |
US9139651B2 (en) | 2015-09-22 |
IL207688A0 (en) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11312779B2 (en) | Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions | |
US8926957B2 (en) | Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells | |
AU2012202218B2 (en) | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |